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Cell-surface receptors on immune cells direct immune-cell function by sensing and 
responding to signs of pathogens and tissue damage. Signaling initiated by 
immunoreceptors is responsible for essential aspects of the immune response, including 
phagocytosis by myeloid cells, and antigen sensing by B and T cells. Efficient regulation 
of immunoreceptor signaling ensures that inflammation arising from pathogen clearance 
is limited in order to prevent tissue damage. Autoimmune diseases, such as systemic 
lupus erythematosus, can occur when these signaling pathways are improperly 
regulated. The tyrosine kinase Lyn is an important regulator of immune function due to 
its unique ability to both initiate signaling that can generate inflammation, and also recruit 
and activate proteins that dampen cellular activation. Alterations to Lyn expression and 
signaling in both human and mice can worsen or cause autoimmune disease. 
Understanding how Lyn is regulated and balances these roles is necessary to develop 
therapies that selectively limit autoinflammation but preserve pathogen clearance. 
Alternative splicing of the lyn gene produces two proteins, LynA and LynB, that differ by 
the presence of a 21-amino-acid insert present in LynA and absent in LynB. Here, we 
demonstrate the LynA and LynB are differentially regulated in immune cells. 
Phosphorylation of LynA at Tyrosine 32 in its unique region causes LynA to be rapidly, 
and selectively, poly-ubiquitinated by an E3 ligase, c-Cbl, and degraded. We show that 
differential expression of c-Cbl in macrophages and mast cells controls LynA protein 
levels, degradation, and signaling responses following Src-family kinase activation. 
Furthermore, we created novel knockout mice to study the roles LynA and LynB play in 
regulating autoimmune disease. Using these novel mice, we show that LynB prevents 
the development of splenomegaly and autoimmunity by limiting myeloid cell expansion 
and B cell activation. We also demonstrate that LynB-deficient mice have elevated 
responses to Toll-like receptor activation. Together, these results indicate that LynA and 
LynB are differentially regulated and have unique roles in the immune response. 
Therefore, understanding LynA and LynB signaling and regulation could yield targets 
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CHAPTER 1: Introduction 
 
1.1 Receptor diversity, signaling commonalities 
The cells that comprise the immune system are diverse in nature, spanning short-lived 
innate immune cells such as neutrophils, which circulate through blood and lymph, 
patrolling for signs of infection and tissue damage, to long-lived tissue-resident 
lymphocytes and macrophages, which maintain tissue homeostasis while also acting as 
sentinels for infection. The diversity of immune cells allows the immune system to 
accomplish a diverse set of responsibilities, including, but not limited to, protecting 
against and eliminating pathogens, managing a diverse microbiota [1], directing organ 
development [2], eliminating apoptotic cell debris [3-5], preventing and eliminating 
cancerous cell growth [6-8], facilitating wound repair [9, 10], and monitoring and directing 
synaptic transmission and neuronal function [11]. To accomplish these varied tasks, 
immune cells express a panoply of receptors that respond to diverse environmental cues 
and subsequently direct immune function. Suprathreshold receptor ligation initiates 
signaling that directs an appropriate immune response. Ensuring that cues sensed by 
these receptors are properly integrated and regulated is absolutely critical to ensure that 
inflammation driven by an immune response is limited in scope to prevent tissue 
damage. Diseases such as cancer [7], lupus [12, 13], atherosclerosis [14] and other 
autoinflammatory diseases, and can occur when these systems are improperly 
regulated. 
 
Intracellular tyrosine kinases are important mediators of immunoreceptor signal 
transduction and regulate immune-cell activation, proliferation, survival and the immune 
response to pathogens [15]. The transfer of the terminal phosphate of ATP to a tyrosine 
residue on a protein substrate results in changes in conformation and protein-protein 
interactions that act as signals to direct cellular function [16]. Although the growth, 
survival, and proliferation functions of tyrosine kinases are important in all cells, immune 
cells employ peculiar binding motifs, alternative expression of kinase family members, 
and additional receptor families for additional functionalities such as phagocytosis, 
antigen-specific signaling, and polarization. In lymphocytes, Src-family kinases (SFKs) 
initiate signaling downstream of T- and B-cell receptors by phosphorylating 
immunoreceptor tyrosine-based activation motifs (ITAMs), which lead to the activation of 
the tandem-SH2-containing tyrosine kinases Syk and Zap-70 [17, 18]. Together, these 
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tyrosine kinases activate FAK-family tyrosine kinases (FAK, Pyk2) and Tec-family 
tyrosine kinases (Btk, Itk, Tec [19]). Parallel pathways are activated upon Fc-receptor 
engagement in myeloid and NK cells. ITAM-coupled receptor activation and tyrosine 
kinase signaling is a major driver of the anti-pathogen response and can induce T cell 
activation, proliferation and degranulation; production of antibodies by B cells, pathogen 
engulfment (phagocytosis) by myeloid cells, and cytokine release and degranulation  by 
NK cells [18, 20-23]. Janus-Kinase (JAK) activation downstream of membrane-proximal 
tyrosine kinase activation is critical for activation of Signal Transducer and Activator of 
Transcription (STAT) proteins that mediate growth, differentiation, and polarization [24] 
of immune cells in response to cytokines. Other receptor-tyrosine kinases such as Flt3, 
c-Kit, and Tyro/Axl/Mer control cell survival, differentiation and many other essential 
functions of immune cells [25, 26]. Despite the many inputs that engage tyrosine kinases 
and an intense research focus on the tyrosine kinases involved in immune activation, we 
are still discovering elements of the interactions and dynamics of tyrosine kinases that 
have profound effects on immune regulation [19, 22, 27-29]. Understanding the 
dynamics, kinetics, substrates, and scaffolding interactions of tyrosine kinases is critical 
to developing therapeutics that modulate immune function [13, 29, 30]. The research 
presented in this dissertation provides new insights into tyrosine kinase regulation and 




1.2 The Src-family kinases: structure and activation 
1.2.1 Family members and structure 
The SFKs in particular are critical for many aspects of immune activation. The SFKs 
comprise a group of eight evolutionarily and structurally related nonreceptor-tyrosine 
kinases [31-33]. The SFKs can be divided into two families differentiated by sequence 
similarity. The Lyn subfamily includes Lyn, Hck, Lck and Blk, while the Src subfamily 
includes Src, Yes, Fyn and Fgr [32]. Different immune cells express different SFKs, 
lending diversity to the regulation of similar signaling pathways. Notably, T cells primarily 
express Lck and Fyn, B cells primarily express Blk, Lyn, and Fyn, while myeloid cells 
express various combinations of Lyn, Hck, Fgr, Fyn and Src [32]. 
 
The SFKs share a similar domain structure (Figure 1.1A), with N-terminal 
palmitylation/myristylation sites followed by a disordered (or loosely ordered), unique 
region, Src-homology (SH)3, and SH2 domains, and ending with a two-lobed kinase 
domain. Lipidation anchors the SFKs to the inner leaflet of the plasma membrane and 
ensures proper microlocalization within membrane subdomains [34, 35]. The unique 
region is the least conserved element of the SFKs. Although other domains of the SFKs 
have been crystallized and structurally characterized, the unique region is relatively 
disordered, and not amenable to crystal structure analysis. Therefore, there is little 
structural information about the unique region. However, studies have shown that this 
region mediates important protein-protein interactions; for instance, the unique-region of 
Lck contains a Zinc-clasp structure that mediates the interaction of Lck with the T-cell 
coreceptors CD4 and CD8 [36, 37]. In most SFKs, the unique region may be post-
translationally modified by phosphorylation or carbohydrate conjugation [38-40] to alter 
kinase function and interactions. In addition, the unique region can make intramolecular 
contacts that may alter kinase activity [41, 42]. Portions of this dissertation expand our 
knowledge on how the unique region regulates kinase function.  
 
The SH3 and SH2 domains are well characterized structurally and have both regulatory 
and protein-protein interaction functions [43]. The SH3 binds intramolecular polyproline 
motifs [44] that keep the kinase in a closed confirmation, but also binds extramolecular 
polyproline motifs that help transmit signals. Similarly, the SH2 domain binds intra- and 
extra-molecular phosphorylated tyrosines [45] that serve similar purposes. The kinase 
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domain is responsible for transferring the terminal phosphate of ATP to a tyrosine 






Figure 1.1. SFK structure and conformations. (A) Schematic of SFK structure (B) 
SFK in both inactive and active conformations, illustrating intramolecular interactions 
between the SH3 domain and polyproline motifs (P P P) in the linker region; and the 





1.2.2 Intrinsic regulation of SFK activation 
The kinase activity of the SFKs is subject to intramolecular regulation. In the inactive 
state, the SFKs are kept in a closed conformation that limits full kinase activity by 
blocking substrate binding and protein-protein interactions. (Figure 1.1B). In this state, 
the SH3 domain is bound to poly-proline motifs in a linker region that connects the SH2 
domain to the kinase domain [46]. Similarly, the SH2 domain is bound to a 
phosphorylated tyrosine, tyrosine 527 (Y527 in the classical chicken, c-Src, numbering), 
on the C terminus [47, 48]. Activation of the kinase requires Y527 dephosphorylation, 
which opens the kinase and allows the SH3 domain to bind polyproline motifs in other 
proteins, further promoting an active conformation [49]. Phosphorylation of a tyrosine in 
the activation loop, Y416 (Figure 1.1B), is required for full kinase activity. The activation 
loop is important for binding magnesium, Mg2+, that coordinates ATP binding in the 
active site. Phosphorylation at Y416, often provided via trans-autophosphorylation from 
other SFKs, induces a structural change that allows ATP and ligand binding in the active 
site of the kinase domain [50, 51]. Although full activation requires dephosphorylation of 
Y527 and phosphorylation of Y416, SFKs can adopt many conformations along a 
continuum of activation, with varied effects on kinase activity [52-54]. Additionally, post-
translational modifications of other sites on the kinase can modulate kinase activity. 
Portions of this dissertation discuss some of these regulatory sites and mechanisms. 
 
1.3 Regulation of SFK signaling and immune activation 
1.3.1 Kinetic segregation and receptor clustering 
Balancing Y527 and Y416 phosphorylation is critical for regulating the signaling ability of 
the SFKs. In immune cells, dephosphorylation of Y527 is primarily provided by the 
receptor-tyrosine phosphatases CD45 (Ptprc) and CD148 (Ptprj) [28, 55-57] and 
phosphorylation of Y527 is maintained by the kinase Csk [58]. The balance between 
CD45/148 and Csk regulates the pool of active SFK within the cell and subsequent 
downstream signaling generated by the SFKs. 
 
Although CD45 and CD148 are required to initiate the process of SFK activation, both 
phosphatases also have the ability to dampen receptor signaling by dephosphorylating 
the SFK activation-loop tyrosine, Y416, and the ITAMs themselves [59]. Therefore, 
phosphatase localization and activity must be regulated to ensure maximal SFK signal 
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transduction. Kinetic segregation (Figure 1.2A) is a useful model that explains many 
aspects of how CD45/148 localization permits SFK activation and signal transduction. 
While most ITAM-coupled receptors have relatively small extracellular domains, on the 
order of ~5 nm [60], CD45 and CD148, have tall and rigid extracellular domains, 20-50 
nm in length.[57, 61]. At steady-state, diffusion of phosphatases and receptors in two 
dimensions across the plasma membrane promotes a basal level of tonic signaling as 
CD45/148 dephosphorylate SFK Y527, and also limits the amplification of this signaling 
by dephosphorylating Y416, and ITAMs. However, when ITAM-coupled receptors are 
engaged by ligands, the bulky extracellular domains force the phosphatases to become 
excluded from a zone of diffusing ITAM-coupled receptors, known as the immunological/ 
phagocytic synapse [62, 63]. SFKs entering this exclusion zone are initially 
dephosphorylated at Y527 by the excluded phosphatases, and then subsequently 
protected by the absence of phosphatase in the synapse, allowing for ITAM 
phosphorylation and activation  of Syk/Zap-70 which activates further downstream 
signaling [63]. Removing the bulky extracellular domain of CD45 and CD148 has been 
shown to alter phosphatase localization and abrogate SFK-mediated signaling. 
 
The degree of receptor clustering (Figure 1.2 B-C) influences signaling outcomes in 
immune cells as well. While low-valency (nanoclustering) receptor ligation can exclude 
CD45/148 and activate the SFKs, it is not enough to induce cellular activation [62, 64, 
65]. Signaling events and Zap-70 recruitment are partially controlled in T cells by the 
degree of receptor clustering [65]. Phagocytic cells, such as neutrophils and 
macrophages, have the ability to identify ITAM-receptor ligands associated with intact 
pathogens by sensing the degree of ITAM-clustering as a proxy for the size of the 
interacting surface. For instance, neutrophil extracellular trap (NET) release is more 
likely to occur in response to large fungal hyphae than smaller yeast cells [66, 67]. 
Similarly, the production of reactive oxygen species (ROS) and IL-6 in macrophages is 






Figure 1.2. Kinetic segregation and receptor clustering. (A) Schematic of kinetic 
segregation illustrating phosphatase exclusion during Fc Receptor mediated formation of 
a phagocytic synapse. (B-C) Receptor clustering increases the degree of phosphatase 
exclusion and SFK activation.  
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1.3.2 Limitations of the kinetic segregation model 
Although kinetic segregation is a useful model for understanding many aspects of SFK 
regulation, several studies have suggested that additional regulatory mechanisms 
influence immune activation. The phosphatases CD45 and CD148 are exceptionally 
efficient enzymes (Tanya Freedman, data unpublished). CD45 is also one of the most 
abundant proteins on the immune cell surface [68]. The high efficiency and expression of 
CD45 results in a considerable pool of active SFKs within resting cells [69]. Because this 
pool of active SFK is unable to induce effective downstream signal activation, additional 
regulatory elements must be present that regulate SFK activation and signaling. Pivotal 
studies using macrophages and T cells from CskAS transgenic mice have revealed other 
regulatory elements important for signal transduction following SFK activation. The 
CskAS system utilizes a designer version of Csk that can be specifically inhibited by the 
small molecule 3-IB-PP1 (Figure 1.3) [70]. In both T cells and macrophages that 
express CskAS, 3-IB-PP1 treatment induces robust SFK activation in the absence of any 
phosphatase exclusion or receptor ligation. Despite this strong initiation of signaling, 
Csk-inhibition fails to generate downstream markers of cellular activation, such as MAPK 
or Akt activation-loop phosphorylation, in both T cells and macrophages [22, 71]. In T 
cells, this signaling blockade can be overcome by cotreating with small molecules that 
induce remodeling of the actin cytoskeleton [71]. Actin corrals can restrict receptor 
diffusion and prevent full-scale receptor clustering, and the importance of actin in 
restricting cellular activation by limiting receptor diffusion is supported by other work [72-
74]. Interestingly, in macrophages, actin remodeling fails to restore cellular activation in 
response to 3-IB-PP1-induced SFK activation, showing that regulation of SFK signaling 
differs by cell type. In macrophages, the signaling blockade is restored by pretreating 
(priming) the cells with inflammatory cytokines, which induces changes in protein 
expression, particularly the upregulation of the SFKs Lyn and Hck [22]. The ability of the 
SFKs to induce downstream signal transduction in primed macrophages upon 3-IB-PP1-
induced activation was further shown to depend on Lyn. Actin-restricted receptor 
diffusion and regulation of the protein levels of receptors and signaling molecules are 
two mechanisms that work in concert with phosphatase exclusion to regulate SFK 
activation and signaling. The difference in SFK signaling between macrophages and T 
cells, illustrated by studies with CskAS mice, show that SFK signaling is also regulated in 
a cell-specific manner. Portions of this dissertation expand on some of the regulatory 
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mechanisms that function independently of kinetic segregation to control SFK signaling 






Figure 1.3 The analog-sensitive kinase CskAS. (A) The analog-sensitive kinase CskAS 
is inhibited by the bulky PP1 analog 3-IB-PP1, leading to Src family kinase (SFK) 
activation and subsequent activation of Syk tyrosine kinase. (B) Crystal structure of Csk 
(gray; PDB ID: 1K9A;[75]) modeled with the ATP binding site occupied by a bulky analog 
of the kinase inhibitor PP1 (3-MB-PP1; red). The box outlines the zoomed images in the 
following panel. Image rendering and modeling was performed in Pymol.(C) Zoomed 
views of wild-type (WT) and (modeled) CskAS with the gatekeeper (residue 266) 
highlighted in yellow. Threonine-to-glycine substitution of the gatekeeper residue 
(T266G) enlarges the ATP binding pocket, accommodating the bulky inhibitor. Wild-type 





1.3.3 Non-receptor phosphatases and ubiquitin ligases 
Additional regulatory mechanisms both prevent and dampen signal transduction by the 
SFKs. Non-receptor phosphatases such as SHP-1/2, PTPN22 (also called Lyp in 
humans or PTP-Pep in mice), and SHIP-1 are important regulators of SFK- and tyrosine-
kinase signaling. In immune cells, SHP-1 and SHP-2 associate with immunoreceptor 
tyrosine inhibitory motifs (ITIMs) present within receptors such as FcγRIIb and Sirpα [76, 
77]. ITIMs contain a single tyrosine site of phosphorylation, that, like ITAMs, is 
predominantly phosphorylated by the SFKs [18]. Upon ITIM phosphorylation, the SH2 
domains found within SHP-1 and SHP-2 bind the phosphorylated ITIMs and are 
recruited from the cytoplasm to the plasma membrane, into close proximity to the SFKs, 
Syk/Zap-70 and phosphorylated ITAMs, which can be subsequently dephosphorylated 
by the SHP-1 and SHP-2 phosphatase domains. In accordance with kinetic segregation, 
failure to exclude ITIM-coupled receptors from the immunological synapse can dampen 
SFK signaling and cellular activation [78, 79]. The importance of SHP-1 to immune 
regulation is especially illustrated by the stark phenotype of SHP-1KO mice [80]. Due to 
inflammation triggered by unrestrained myeloid activation and proliferation, SHP-1KO 
mice develop pneumonia and skin lesions that have led this mouse strain to be 
commonly referred to as the “motheaten” mouse. Although SHP-2KO mice suffer from 
embryonic lethality, this is not a result of immune activation but rather due the 
importance of SHP-2 for gastrulation. Interestingly, selective deletion of SHP-2 in T, B 
and myeloid cells has revealed contrasting roles for SHP-2 in both limiting ITAM and 
cytokine receptor signaling, and promoting activation of mitogen-activated protein kinase 
(MAPK) signaling pathways, lending complexity to the regulatory mechanisms that 
control immune activation [81, 82]. 
 
Ubiquitin ligases are important regulators of tyrosine kinase activity. The conjugation of 
ubiquitin to proteins can lead to conformational changes, cellular re-localization and 
protein degradation by both the lysosome and proteasome [83]. The Cbl family of 
ubiquitin ligases, which include the proteins c-Cbl and Cbl-b, are especially important 
regulators of both the SFKs and other tyrosine kinases in immune cells [84]. Both c-Cbl 
and Cbl-b contain structural elements that mediate strong interactions with the SFKs, 
including an SH2-like domain that can bind phosphorylated tyrosines on the SFKs, poly-
proline motifs that can interact with the SFK SH3 domain, and tyrosine phosphorylation 
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sites that can interact with the SFK SH2 domain [84-86]. In addition, c-Cbl requires 
phosphorylation by SFKs to become activated [87, 88]. The importance of c-Cbl and Cbl-
b in regulating SFK signaling has been demonstrated in both mice and humans. 
Mutations in c-Cbl that abrogate ubiquitin-ligase activity are found in leukemias, leading 
to increased SFK-mediated phosphoinositide 3-kinase (PI3K) signaling and cancer cell 
growth [89, 90]. Similarly, deletion of c-Cbl and Cbl-b in immune cells alters antigen 
receptor signaling in T cells, impairing receptor internalization, promoting cellular 
proliferation and causing defective positive selection in T cells [91-93]. Ubiquitin ligase 
activity by c-Cbl and Cbl-b also regulates B-cell-receptor recycling and localization, and 





1.4 Role of the SFK Lyn in immune signaling 
1.4.1 Multiple roles for Lyn in regulating immune function 
Lyn has long been a kinase of interest to immunologists. The lyn gene was first identified 
in 1987 via a cDNA screen as putative tyrosine kinase with similar structure to the 
previously identified SFKs Yes, Lck, Src and Fgr [101], and its tyrosine kinase activity 
was demonstrated shortly thereafter [102]. In 1991 Lyn was shown to be expressed in B 
cells, co-immunoprecipitate with the B cell receptor (BCR), and become phosphorylated 
following BCR stimulation. Crosslinking the BCR was shown to activate Lyn and cause it 
to bind the non-catalytic subunit of PI3K [103, 104]. Similarly to the BCR, Lyn could be 
co-immunoprecipitated with the ITAM-coupled FcεR in mast cells, activated following 
FcεR crosslinking, leading to the activation of phospholipases [105-107]. Further 
research showed that Lyn was expressed in platelets and associates with CD36, was 
expressed in monocytic cells [108, 109] and activated downstream of GM-CSF-receptor 
ligation [110]. 
 
These early studies suggested that by activating PI3K and phospholipase signaling 
downstream of ITAM-coupled receptors and cytokine receptors, Lyn functions 
redundantly to other SFKs in immune cells. However, in 1995 the development of gene 
targeting in embryonic stem cells allowed LynKO mice to be created. Studies from these 
mice revealed that Lyn had a unique role in suppressing immune function. Using LynKO 
mice, the Dunn group discovered that Lyn was required for the proper development of 
several types of immune cells [111]. Like some of the previously described severely 
immunocompromised mice at that time, such as the BtkKO and motheaten (SHP-1KO) 
mice, LynKO mice had a marked reduction in B cells, resulting from a defect in B cell 
development, particularly in the transition of Pro/Pre-B cells to mature B cells. In 
addition, at roughly 10 months of age the LynKO mice developed symptoms similar to the 
human autoimmune disease, systemic lupus erythematosus (SLE). Despite the defect in 
B cell formation and maturation, LynKO plasma cells produced increased levels of 
circulating antibodies and produced anti-nuclear antibodies. The production of 
autoreactive antibodies that become deposited in the kidney promotes inflammation and 
kidney damage (glomerulonephritis). In parallel studies [112], The Yamamoto group 
demonstrated similar findings (defects in B cell maturation and the development of 
Lupus-like pathologies), but also noted the development of splenomegaly in LynKO mice, 
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largely due to the increased presence of Mac-1+ (CD11b+/CD18+) cells, including 
monocytes, granulocytes and innate-like B-1 B cells. These two pivotal studies 
demonstrated that Lyn has a surprising role in negatively regulating the immune system, 
in contrast to the other SFKs expressed in immune cells. 
 
A number of proteins and signaling cascades were shown to be critical for driving 
autoimmunity in the absence of Lyn. Cytokines like IL-6, BAFF, and IFN-γ ,[113, 114] 
and cytokine receptors, such as the IL-5Ra [115] were shown to promote 
autoinflammation and myeloproliferation in LynKO mice. Proteins associated with actin 
rearrangement like Ezrin [116] and signaling proteins downstream of Lyn, including PI3K 
and Btk, have also been shown to mediate autoimmune disease in LynKO mice.  
 
Components of Toll-like Receptor (TLR) signaling, including the adaptor proteins MyD88 
[117, 118] and CARD9 [119] , and the transcription factor IRF5 [120] were also shown to 
promote disease in the absence of Lyn. The Toll-like receptors are a group of receptors 
that sense components of bacterial, fungal and viral antigens, including 
lipopolysaccharides (LPS) derive from gram-negative bacteria, and single-stranded DNA 
derived from bacteria and viruses. The link between Lyn and TLR signaling was first 
illustrated in 1993, when Lyn was shown to co-immunoprecipitate with CD14, and be 
activated following LPS treatment of human monocytes [121]. However, a clear 
understanding of Lyn’s role in TLR signaling remains elusive, likely due to differences in 
TLR signaling in different cell types. Lyn-deficient dendritic cells have elevated signaling 
responses and secrete more cytokines following treatment with ligands that activate the 
MyD88-dependent TLR4 (LPS) and TLR9 (CpG) [117, 119, 122]. Lyn has been shown to 
both positively and negatively regulate plasmacytoid dendritic cell (pDC) TLR signaling, 
depending on the method of TLR-agonist treatment [117, 123]. When pDCs are treated 
with CpG, Lyn is required for Type I Interferon production because Lyn promotes proper 
endosomal tracking and delivery of CpG to endosomal TLR9 [123]. Likewise, research 
has demonstrated conflicting roles for Lyn in macrophage TLR signaling. Some studies 
have demonstrated a negative role for Lyn in TLR4-related signaling [124],  while others 
have demonstrated a minimal role for Lyn in the macrophage response to TLR receptor 
activation [119]. Finally, Lyn has been shown to be required for optimal cytokine release 




TLRs themselves and TLR signaling are strongly linked to autoimmune and 
autoinflammatory diseases in both humans and mice. Lupus patients have increased 
TLR4, TLR7 and TLR9 expression, which is associated with worse lupus pathology [126, 
127]. Overexpression of TLR7 and chronic TLR7 and TLR9 signaling induces 
autoimmune disease in mice [128-130]. Similarly, TLR4 is required for kidney pathology 
in some mouse autoimmune disease models [131]. Portions of this dissertation present 
new evidence examining the role for Lyn in TLR signaling and autoimmune disease 
development. 
 
In mature follicular B cells, Lyn deletion causes both a delay and an amplification of BCR 
signaling, while simultaneously making cells more resistant to apoptosis, pushing cells 
towards an activated state, and promoting differentiation to plasma B cells [12, 132]. 
While initial animal studies were made using germline deletion of Lyn, genetic deletion of 
Lyn solely in B cells using Cre recombinase under the CD79a promoter showed that 
LynKO B cells alone could induce autoimmunity and myeloproliferation [118]. Parallel 
studies using selective deletion of Lyn in dendritic cells via CD11c-cre revealed a critical 
role for dendritic-cell involvement in Lyn-mediated suppression of autoimmunity [117]. 
LynKO conventional dendritic cells (cDC’s) express higher levels T-cell-costimulatory 
molecules such as CD80 and CD86 and secrete higher levels of cytokines in response 
to TLR ligation. 
 
While the proteins and cell types involved in autoimmunity development in Lyn-deficient 
mice were being discovered, so were the proteins involved in Lyn-mediated immune 
suppression. Early work defined the ability Lyn to co-immunoprecipitate and 
phosphorylate CD22 and FcγRIIb on B cells and mediate recruitment and 
phosphorylation of the phosphatases SHP-1, SHP-2, and SHIP-1 [112, 133, 134]. The 
integrin CD11b was shown to recruit Lyn and SHP-1 and dampen B cell and dendritic 
cell activation [119, 135]. Furthermore, Lyn-deficiency has been shown to mediate 
human SLE pathogenesis. Some patients with lupus have decreased B-cell-Lyn 
expression or altered Lyn trafficking [136-138]. Polymorphisms in the LYN gene are also 
enriched in patients with lupus [139], suggesting that like mice, Lyn plays a prominent 




While Lyn is most well-known for its role in negatively regulating immunoreceptor 
signaling, Lyn does have prominent roles in promoting cellular activation as well. In 
contrast to follicular B cells, B1 B cells, which respond to T cell-independent antigens, 
require Lyn for downstream signaling in response to BCR ligation [140]. In B1 B cells, 
CD148 preferentially activates Lyn upon BCR ligation. CD148 is highly expressed in B 
cells and myeloid cells, and in macrophages, Lyn is activated more rapidly than other 
SFKs [22] as well. Similarly to BCR signaling, Lyn has positive and negative roles in 
mast-cell-FcεR1 signaling. The different roles for Lyn in FcεR1 signaling likely depend, at 
least in part, on the strength of stimulation [141]. In mast cells, Lyn is required for 
MAPK/Erk and Akt activation in response to low concentrations of stimuli, yet also 
required for effectively regulating/dampening MAPK and Akt activation in response to 
high stimuli concentrations. FcγR-mediated phagocytosis-induced signaling is defective 
in LynKO macrophages as well [142]. LynKO mice are also less able to survive infection 
with certain pathogens, including Salmonella typhimurium and Pseudomonas 
aeruginosa [119, 143-145]. In both respiratory and enteric infection models, LynKO mice 
suffer from increased bacterial burden and increased cytokine secretion. While 
increased cytokine production in response to pathogens may result from a lack of 
negative regulation, Lyn appears required for proper pathogen phagocytosis and killing 
[144]. The susceptibility of LynKO mice to pathogenic infection highlights both the positive 
and negative functions of Lyn in immunoreceptor signaling. Understanding how Lyn 
balances these functions, especially with regard to how Lyn regulates signaling across 
different cell types, is critical to understanding the contexts in which immunoreceptor 
signaling promotes diseases such as autoimmunity. 
 
1.4.2 Alternative splicing of lyn: LynA and LynB 
In 1991 mRNA from the lyn gene was shown to produce two alternatively spliced 
proteins, LynA and LynB [146]. LynA and LynB differ by the presence of a 21-amino acid 
insert located in the unique region of LynA, but absent in LynB. Alternative splicing of 
lyn, and the amino-acid sequence of the unique region present in LynA, is highly 





The Yamamoto group was the first to demonstrate that LynA and LynB are differentially 
regulated, noting that the protein levels of LynA were selectively downregulated upon 
antigen stimulation in B cells [148]. In agreement with the Yamamoto study of LynA and 
LynB in B cells, Freedman et. al [22]. demonstrated that LynA was actively degraded 
upon pan-SFK activation in macrophages. The Freedman lab further demonstrated that 
LynA protein levels were critical for determining the sensitivity threshold for downstream 
signaling in macrophages in response to SFK activation. The evidence suggesting that 
LynA may activate downstream signaling more readily than LynB is consistent with other 
studies in mast cells [149] and MDA-MB-231 breast cancer cells [150]. LynKO mast cells 
lentivirally-reconstituted with LynA  showed greater phospholipase activation and more 
readily degranulated upon FcεR ligation, than those reconstituted with LynB. Conversely, 
LynB more readily phosphorylated inhibitory proteins such as SHIP-1, suggesting that 
LynB might play a more prominent role in inhibitory signaling [149]. Similarly, MDA-MB-
231 breast cancer cells selectively expressing LynA have a more invasive phenotype 
than those selectively expressing LynB [150].  
 
SFK signaling induces many aspects of the immune response. As such, SFK signaling 
must be efficiently regulated to insure proper control of inflammation and tissue damage. 
Kinetic segregation, the degree of receptor clustering, ubiquitin ligases and 
phosphatases all work in concert to regulate SFK signaling. The SFK Lyn is particularly 
required for negatively regulating SFK and ITAM-related signaling. The transcript for Lyn 
encodes two proteins, LynA and LynB. This dissertation expands on the regulatory 
mechanisms that control LynA and LynB signaling, and the role the two proteins play in 







Figure 1.4 LynA is highly conserved across species (A) Sequence alignment of ape 
(human, chimpanzee), monkey (rhesus macaque, capuchin), rodent (mouse, rat), and 
marsupial (opossum, wallaby, and platypus) N-terminal Lyn protein sequences. 
Differences from human sequence are marked in red. The LynA insert is marked in blue. 
Sequences obtained from the Universal Protein Resource (Uniprot Entries: P07948, 
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CHAPTER 2: Methods 
 
2.1 Tools for studying tyrosine kinase signaling 
Numerous tools exist for studying the actions of tyrosine kinases in immune cells, 
including genetic methods, such as small interfering RNA (siRNA) knockdown and 
CRISPR/Cas9-based gene editing, small-molecule inhibitors, and designer kinases. 
Each approach has advantages and disadvantages with regard to specificity, temporal 





Method Advantages Disadvantages 
Small-molecule inhibitors 
Inexpensive, Rapid inhibition, 
No genetic compensation 
Poor selectivity,  
Low solubility of inhibitors 
Knockout models 
Specificity,  
No barrier to studies in vivo 
Transcriptional/Post-
translational compensation 
that leads to altered signaling, 
Time/labor intensive, 
Expensive to maintain 
Analog-sensitive kinases 
Rapid kinase inhibition, 
No transcriptional feedback, 
Portable and robust 
Time- and labor-intensive 
design/screening 
Immunoblotting 
Detection of low-abundance 
proteins,  
Wide compatibility 
Low throughput,  





Can reveal novel 
phosphorylation sites  
Limited quantification (no 
protein standards),  
Limited sensitivity, so might 
miss low-abundance proteins 
and rare events 
Targeted proteomics 
Precise quantification, even 
of low-abundant proteins or 
phosphorylation events,  
Does not rely on availability 
of antibodies  
Time- and labor-ine assay 
development,  
Limited scope 
Table 2.1: Advantages and disadvantages of different methods for studying 




Genetic methods are attractive options for studying kinase function because of their 
inherent specificity and stability. While knockout gene-editing strategies are valuable 
because they offer complete disruption of kinase signaling, siRNAs offer inducible 
control over kinase-signaling disruption and supplement knockout strategies when a 
knocking out a given kinase may be lethal to a cell or animal. siRNAs and genetic 
knockouts are routinely used to investigate the importance of specific kinases in immune 
cells. For instance, mice in which the SFK Lyn has been knocked out (LynKO) have 
become important models of autoimmune disease after studies revealed the importance 
of Lyn as a negative regulator of B- and dendritic-cell activation [12, 151]. Tyrosine-
kinase knockouts can also be coupled to Cre-lox and FLP-FRT systems for cell-specific 
knockout [117, 118]. The advent of CRISPR-Cas9 gene editing has facilitated the 
substitution of specific amino acid residues in knock-in models, allowing researchers to 
dissect novel elements of tyrosine kinase function [152]. The major drawback of genetic 
knockout and knockdown models for studying kinase signaling is that cells often develop 
compensatory mechanisms for coping with the loss of given kinase. These feedback (or, 
in cell lines and aging animals, cellular-evolutionary) effects may mask the normal 
signaling contributions and scaffolding interactions of the kinase of interest [153, 154]. 
 
Small-molecule inhibitors have facilitated the study of kinases in many aspects of 
immune activation. Kinase inhibitors generally function by competing with ATP for 
access to the active site, preventing substrate phosphorylation [155]. Although many 
compounds are marketed for inhibition of specific kinases, caution should be used when 
choosing an inhibitor and interpreting its effects on signaling. ATP-binding sites are 
highly conserved across the kinome [156], and most inhibitors target multiple kinases, 
either within a family or in different branches of the kinome [157]. Researchers should 
familiarize themselves with these off-target effects and use the lowest effective 
concentration of inhibitor to disfavor weaker binding interactions. Furthermore, many 
kinase inhibitors are poorly soluble in aqueous buffers, necessitating formulation for in 
vivo experiments or pre-treatment for in vitro experiments [158, 159]. A final 
consideration when working with ATP-mimetic inhibitors is that these inhibitors typically 
bind and may even induce the active conformation of the kinase. This can lead to a 
paradoxical increase in typical readouts of kinase activation (e.g. phosphorylation of the 
activation-loop tyrosine) and may even ultimately promote signaling due to release of 
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autoinhibition. Careful controls, for example assaying phosphorylation of 
inhibitory/activating sites on the kinase and direct substrates should be probed along 
with downstream readouts of cell activation. Ultimately, however, small-molecule 
inhibitors for many kinases are well characterized, commercially available, and require 
little up-front investment of time or resources. Moreover, a pharmacological approach 
can uniquely enable the study of transient effects with high kinetic fidelity and minimal 
regulatory compensation. Inhibitors are thus powerful tools for dissecting kinase 
contribution to immune activation. Inhibitors also have the advantage of potentially 
preserving scaffolding interactions of the target protein, unlike genetic knockout and 
knockdown methods. 
 
Chemical-genetic methods for studying kinase signaling in immune cells combine the 
specificity of gene editing with the temporal control of small-molecule inhibitors. In one 
approach, kinases are sensitized to a bulky analog of an ATP-competitive kinase 
inhibitor by substituting a smaller amino-acid side chain for the usual aliphatic, polar, or 
bulky gatekeeper residue [160]. Since the gatekeeper is not directly involved in ATP 
binding, the “analog-sensitive” (AS) kinase is functionally active until the designer inhibitor 
is added [161]. This chemical-genetic approach can be used in transfected/transduced 
cells or incorporated into the genome of a model animal as a transgene or knock-in. 
Since endogenous kinases have more occlusive gatekeeper residues, the engineered 
kinase-inhibitor pair is much more specific than traditional kinase inhibition. Importantly, 
analog-sensitive kinase inhibition has the additional advantage over genetic or siRNA 
knockout approaches in that normal kinase function in the absence of inhibitor will allow 
direct comparison of cells pre- and post-treatment. This real-time component also 
minimizes the likelihood of compensatory transcriptional changes and other adaptations 
in primary cells or animals and selective pressure and evolution in cell lines. This 
approach has been used to identify the specific roles for Zap-70 in T-cell activation and 
Csk in T-cell and macrophage activation, and has been applied to other kinases as well 
[22, 71, 162]. Furthermore, although many kinase inhibitors blunt signaling, some 
kinases, such as Csk, have negative-regulatory functions. Inhibition of analog-sensitive 
Csk (CskAS) with 3-IB-PP1 leads to robust Src-family kinase (SFK) activation [22, 71]. 
Inhibition of this negative-regulatory kinase can be used as potent stimuli of cellular 
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signaling and can be combined with other kinase inhibitors to elucidate kinase 
contributions to cellular activation and protein dynamics [27]. 
 
Although some information can be gleaned from unbiased total-protein and pan-
phosphotyrosine detection methods, immunoblotting is typically most effective when 
applied as a targeted, relatively low-throughput process, requiring antibodies raised 
against unique peptide sequences or sites of posttranslational modification. The best 
antibodies have minimal cross-reactivity with other molecules in the cell. Small-volume, 
higher-throughput apparatuses are available, but these systems are less amenable to 
combining antibodies and resolving multiple species in a single blot. Despite these 
caveats, immunoblotting remains a robust, sensitive, and adaptable technique [163]. If 
epitope-specific antibodies are unavailable, immunoblotting can be combined with 
immunoprecipitation. For example, total protein immunoprecipitation can be followed 
with a pan-phosphotyrosine blot, and molecular-weight can be used to infer the identity 
of phosphorylated protein [22]. Alternatively, cyanogen-bromide fragmentation [164] can 
resolve phosphorylation of individual sites on multiply-phosphorylated proteins.  
 
Freed of the requirement for specific antibodies, liquid chromatography mass 
spectrometry (LC-MS/MS) is an excellent exploratory technique for quantifying poorly-
studied proteins and sites of post-translational modification. This methodology is 
especially useful for multiply-modified proteins that cannot easily be probed by blotting. 
Advances in LC-MS/MS have allowed researchers to quantify tyrosine phosphorylation 
via targeted and unbiased approaches [165-167]. Proteomics approaches use 
databases to identify enzyme-digested peptides following resolved by LC-MS/MS. 
Unbiased LC-MS/MS can identify novel sites of phosphorylation in a cell lysate or but 
may miss low-abundance peptides. In contrast, targeted approaches using isotope-
labeled reference peptides are highly sensitive and can be used to quantify abundance 
or novel sites of post-translational modification in both cell lysates, but also in vitro 




Work presented in this dissertation uses knockout and knockdown models, CRISPR-
Cas9 gene editing, analog-sensitive kinases, small-molecule inhibitors, immunoblotting 
and mass spectrometry to dissect the unique regulatory mechanisms and functions of 





2.2 Experimental methods 
2.2.1 Mice 
C57BL/6-derived CskAS mice are hemizygous for the CskAS BAC transgene on a Csk-/- 
background, as described previously [22, 71]. CskASCblb-/-(Csk-/-) mice were generated 
by crossing Cblb-/- female mice from M. Farrar (University of Minnesota) [91] with Csk+/- 
and CskAS male mice from our colony and then crossing Csk+/-Cblb-/- with CskASCsk+/-
Cblb-/- mice. Due to sterility of Cbl-/- male mice, we were not able to produce a sustained 
lineage of CskASCbl-/-(Csk-/-) mice, but we obtained three individuals by crossing Cbl-/- 
female mice from E. Peterson (University of Minnesota) [168] with Csk+/- and CskAS male 
mice from our colony and then crossing Cbl+/-Csk+/- with CskASCbl+/- mice. All mice were 
housed in specific pathogen-free conditions and genotyped using real-time PCR 
(Transnetyx, Inc., Memphis, TN). All animal use complies with University of Minnesota 
(UMN) and National Institutes of Health (NIH) policy (Animal Welfare Assurance Number 
A3456-01). UMN is accredited by AAALAC, and all animal use was approved by the 
UMN Institutional Animal Care and Use Committee (IACUC, protocol # 1910-37487A). 
Animals are kept under supervision of a licensed Doctor of Veterinary Medicine and 
supporting veterinary staff under strict NIH guidelines. 
 
2.2.2 DNA constructs and mutagenesis 
Plasmids containing c-terminally His6V5-tagged mouse LynA and LynB were gifts from J. 
Rivera/R. Suzuki (National Institutes of Health) [149]. Myc-tagged mouse memCskAS 
[also referred to as Lck11-CskAS, 70] and Xpress-tagged human c-Cbl and Cbl-b [169] 
were gifts from A. Weiss (University of California, San Francisco). Untagged mouse 
Hck56+59, Hck56, Fgr, and FynT (Fyn), and human FynB were gifts from C. Lowell 
(University of California, San Francisco.) Site-directed mutagenesis was performed 
using QuikChange Lightning (Agilent Technologies, Santa Clara, CA) and was used to 
prepare the point mutants referenced in the main text, and also to introduce stop codons 
removing epitope tags from Fgr, LynA, and LynAY32A. Sequences of all constructs were 
verified by Sanger sequencing (GENEWIZ, South Plainfield, NJ). 
 
2.2.3 Jurkat cell lines and transfection 
The Jurkat T-cell strains Clone E6-1 [170] and JCaM1.6 (Lck-deficient) [171, 172] were 
gifts from the laboratories of A. Weiss (University of California, San Francisco) and Y. 
Shimizu (University of Minnesota), respectively. Both cell lines were authenticated by 
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STR profiling and tested negative for mycoplasma (ATCC, Manassas, Virginia). Jurkat 
cell lines were cultured in RPMI-1640 medium supplemented with 5-10% fetal calf serum 
(Omega Scientific, Inc., Tarzana, CA) and 2 mM glutamine, penicillin and streptomycin 
(Sigma-Aldrich, St. Louis, MO) as described previously [173]. Jurkat and JCaM1.6 cells 
were transiently transfected via electroporation, as described previously [173]. Briefly, 
cells were grown overnight in antibiotic-free RPMI-1640 medium supplemented with 10% 
fetal bovine serum (Omega Scientific) and 2 mM glutamine (RPMI10). Batches of 15 M 
cells were resuspended in RPMI10 with 10-15 µg plasmid DNA per construct. Cells were 
rested, electroporated at 285 V/10 ms in a BTX square-wave electroporator (Harvard 
Apparatus, Holliston, MA), resuspended in RPMI10, and allowed to recover overnight. 
One million live cells were then resuspended in phosphate-buffered saline (PBS), rested 
for 30 min at 37C, and stimulated. 
 
2.2.4 Microscopy 
Jurkat cells were transfected with a membrane-anchored CskAS (memCskAS), c-Cbl, and 
LynB (to ensure a response to 3-IB-PP1) along with constructs encoding the unique 
regions of LynA, LynB and LynAY32A fused to eGFP. A construct containing eGFP alone 
was used as a control. 24 hours after transfection, cells were filtered to remove clumps 
of dead cells and resuspended in PBS containing Hoechst Stain (Thermo Fisher) and 
incubated for 30 min at 37°C in a 96-well plate. Cells were then treated with 3-IB-PP1 at 
37°C for 5 min before quenching with ice cold PBS and collected by centrifuging for 5 
min x 1500 rpm at 4°C. Cells were resuspended in ice cold PBS pipetted onto glass 
slides and coverslipped directly before imaging. Cells were imaged using a Leica 
DM600B epifluorescent microscope using DAPI and GFP channels. Exposure times for 
GFP were set to normalize the brightness of the GFP across the different transfection 
conditions, as cell-to-cell expression was variable. Images were pseudocolored and 
merged using ImageJ software (NIH) with the Fiji plugin [174]. 
 
2.2.5 Preparation and flow cytometry of myeloid cells 
BMDMs were prepared using standard methods [56]. Briefly, bone marrow was 
extracted from femura and tibiae of mice aged 6-8-weeks. After hypotonic lysis of 
erythrocytes, BMDMs were derived on untreated plastic plates (BD Falcon, Sigma-
Aldrich) by culturing in Dulbecco’s Modified Eagle Medium (DMEM, Corning Cellgro, 
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Corning, NY) containing approximately 10% heat-inactivated fetal calf serum (Omega 
Scientific), 0.11 mg/ml sodium pyruvate (Corning), 2 mM penicillin/streptomycin/L-
glutamine (Sigma-Aldrich), and 10% CMG-14-12-cell-conditioned medium as a source of 
M-CSF [175]. After 6 or 7 days cells were resuspended in enzyme-free 
ethylenediaminetetraacetic acid (EDTA) buffer and replated in untreated 6-well plates 
(BD Falcon, Sigma-Aldrich) at 1 M cells per well in unconditioned medium with or without 
priming in 25 U IFN-γ (PeproTech, Rocky Hill, NJ). Bone-marrow-derived mast cells 
were prepared as described previously [176], as above except for the substitution of 10 
ng/ml IL-3 (PeproTech) for CMG-14-12-conditoned medium. After 5 weeks, cells were 
subjected to flow-cytometry analysis (LSRFortessa, Becton Dickinson, Franklin Lakes, 
NJ) and found to be uniformly positive for FcεRI (Mar-1, FITC-labeled, #134305) and c-
Kit (2B8, APC-labeled, #105811), both from BioLegend (San Diego, CA). Cells were 
rested or primed overnight before stimulation. 
 
2.2.6 siRNA knockdown of c-Cbl and Cbl-b 
The siRNA sequence for knockdown of mouse c-Cbl was adapted from human siRNA. 
Cbl-b siRNA was designed using the Integrated DNA Technologies double-stranded 
siRNA design tools (IDT, Skokie, IL). Control double-stranded RNA from IDT was not 
predicted to be complementary to any sequence in human, mouse, or rat 
transcriptomes. The effective siRNA sequences from among those we tested are: c-Cbl 
guide sequence CCUACCAGGACAUUCAGAAAGCUUU (passenger sequence 
AAAGCUUUCUGAAUGUCCUGGUAGG), Cbl-b guide sequence 
(CUGACUUCUUGGUAUCUGAUAUATA (passenger sequence 
UAUAUAUCAGAUACCAAGAAGUCAGGU). Aliquots of 2 M BMDMs in 100 l opti-MEM 
(ThermoFisher, Waltham, MA) were transfected with 1 M siRNA via electroporation at 
400 V/10 ms using a BTX square-wave electroporator. Cells were then plated on 150 
mm untreated cell culture dishes and rested in 10 ml DMEM-10 for 30 min before adding 
10 ml DMEM-10 supplemented with 10% CMG-14-12-cell-conditioned medium as a 
source of M-CSF. Transfections were pooled from several cuvettes to obtain enough 
cells for several stimulation conditions. After 24 h cells were resuspended in enzyme-
free EDTA buffer and replated in untreated 6-well plates (BD Falcon, Sigma-Aldrich) at 1 




2.2.7 saRNA enrichment of c-Cbl 
An saRNA sequence designed to upregulate transcription of c-Cbl was designed using 
an algorithm published previously [177]. c-Cbl-targeting saRNA “CBL-Tr-NM_005188-Pr-
30-Cp-0” with guide sequence UCAAUUCUAGAUAAAGGCG (passenger sequence 
CGCCUUUAUCUAGAAUUGA) was ordered from IDT with 2’ O-methylated uracil tails 
(mUmU) to increase transfection efficiency. On the first day of transfection, aliquots of 
105 mast cells were resuspended in 400 µl mast-cell medium in a 24-well plate and 
mixed with 100 µl saRNA+lipofectamine 2000 or 3000 for a final concentration of 5 nM 
saRNA. Cells were then rested overnight before a second transfection with 100 µl 
saRNA+lipofectamine. On day three the cells were transferred into fresh mast cell 
medium and rested overnight. On the day of the experiment, mast-cell aliquots from the 
same saRNA condition were pooled, resuspended in 50 µl DMEM, and rested 2 h before 
stimulation. 
 
2.2.8 Cell stimulation and immunoblotting 
BMDM stimulations have been described previously [22]. After resting as described 
above, 1 M live Jurkat cells, mast cells, or adherent BMDMs were treated at 37C in 
DMEM with 10 µM 3-IB-PP1, a gift from K. Shokat (University of California, San 
Francisco). Signaling reactions were quenched by placing on ice and lysing cells in 
sodium dodecyl sulfate (SDS) buffer (128 mM Tris base, 10% glycerol, 4% SDS, 50 mM 
dithiothreitol (DTT), pH 6.8). Whole-cell lysates were prepared for immunoblotting by 
sonicating with a Bioruptor (Diagenode, Inc., Denville, NJ) for 3 min and boiling for 15 
min. For immunoblotting 0.25 M cell equivalents were run in each lane of a 7% NuPage 
Tris-Acetate gel (Invitrogen, Carlsbad, CA) and then transferred to an Immobilon-FL 
PVDF membrane (EMD Millipore, Burlington, MA). REVERT Total Protein Stain (LI-COR 
Biosciences, Lincoln, NE) was used according to the standard protocol to quantify lane 
loading. After destaining, membranes were treated with Odyssey Blocking Buffer (TBS) 
for at least 1 h. Blotting was performed using standard procedures, and blots were 
imaged on an Odyssey CLx near-infrared imager (LI-COR). Antibodies for 
immunoblotting were purchased from Cell Signaling Technology (Danvers, MA), ProMab 
Biotechnologies (Richmond, CA), Thermo Fisher Scientific (Waltham, MA), Abcam 




2.2.9 Quantification, statistics, and image processing 
Immunoblots were analyzed by densitometry from ImageStudio software (LI-COR 
Biosciences). Images were background-subtracted, and bands of the appropriate 
molecular weight were demarcated and analyzed for each gel lane. Each value was 
corrected for the total lane protein content (REVERT TPS), with the exception of 
pErk1/2, which was corrected with reference to total Erk1/2. Data were further 
normalized to a control condition to show relative changes from a reference state, each-
condition t=0 or reference-condition t=0 as indicated. For all figures, n values are 
biological replicates, reflecting independent experiments from different individual mice 
(except where indicated if sufficient numbers of animals were not available), different 
days and/or batches of cells, stimulus preparations, and experimental workflows. 
Statistical analysis was performed using Prism Software (Graphpad, La Jolla, CA). 
Significance was assessed using one- or two-way ANOVA analysis with Tukey’s or 
Sidak’s correction for multiple comparisons as indicated in the figure legends, with 
analysis of the mean at each time point or condition. Error bars in each figure represent 
standard error of the mean from at least three independent experiments. Asterisks 
reflect specified P-values. Figures were further prepared using Adobe Creative Cloud 
software (San Jose, CA). Where appropriate, images were optimized by applying 
brightness/contrast changes to the whole image. No gamma or other nonlinear 
correction was applied. Images were rotated for figure preparation only after 
densitometry analysis. 
 
2.2.10 Preparation of macrophage samples for targeted mass spectrometry 
analysis 
CskASc-Cbl+/- BMDMs were rested or treated 15 s with 3-IB-PP1, washed with ice-cold 
PBS, and lysed in 1% Lauryl Maltoside Buffer containing 150 mM NaCl, 0.01% sodium 
azide, and protease and phosphatase inhibitors (MSSAFE, Sigma-Aldrich, St. Louis, 
MO). After scraping the plates, cells and detergent were sonicated with a Diagenode 
biorupter for 5 min with a 50% duty cycle. The lysate was then cleared by centrifugation 
for 15 min at 14,000 rpm (16.1x g) at 4°C in a tabletop centrifuge. Lysates were 
precleared for 30 min at 4°C with Protein G Sepharose beads (Sigma-Aldrich) and 
normal rabbit serum (Jackson ImmunoResearch, West Grove, PA). LynA-specific 
antibody [22] (C13F9, Cell Signaling) was pre-bound to Protein-G-Sepharose beads for 
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at least 2 h. A bicinchoninic acid (BCA) protein assay was performed on the whole-cell 
lysates (Thermo Fisher) to ensure that equal amounts of protein from untreated and 3-
IB-PP1-treated cells would be subjected to immunoprecipitation. Lysates were then 
mixed continuously with antibody and beads for 2 h at 4°C to immunoprecipitate LynA. 
Samples were applied to micro bio-spin chromatography columns (Bio-Rad, Hercules, 
CA), washed, and eluted with SDS Sample Buffer containing 125 mM Tris, 10% glycerol, 
5% 2-mercaptoethanol, and 25% SDS. Samples were then concentrated to 40 µl using 
Ultracel-3K centrifugal spin columns (EMD Millipore). Each 40 µl immunoprecipitate 
sample was then resolved by gel electrophoresis. A calibration curve with a bovine 
serum albumin (BSA) standard curve was used to ensure that equal mass quantities of 
immunoprecipitated protein in the untreated and 3-IB-PP1-treated samples would be 
subjected to trypsin digest. For this calibration, we ran 0.05 - 20 µg BSA or the 
immunoprecipitate samples on a 10% Mini-PROTEAN TGX gel (Bio-Rad) at 170 V. Total 
protein was visualized without fixation using SimplyBlue Safestain (Thermo Fisher) 
according to manufacturer's instructions. Following staining, the gel was washed 2 x 1 h 
with water and imaged on a LI-COR Odyssey. The staining intensities were quantified by 
densitometry, and the BSA signals vs. mass quantities were fit to a linear function 
(GraphPad Prism). This function was then used to quantify the mass quantity of total 
protein in each immunoprecipitates. Gel pieces including the lower-MW 
(nonubiquitinated) Lyn species and higher-MW (polyubiquitinated) species were excised, 
spiked with the isotope-labeled LynA Y32 phosphopeptide 
[H]TI[pY]VRDP[13C515N1]TSNK[OH] (Sigma-Aldrich), and subjected to in-gel digestion 
with TPCK-treated sequencing-grade trypsin (Promega, Madison, WI) and STAGE Tip 
peptide cleanup as previously described [178] except that iodoacetamide was used as 
the alkylating reagent. Digested samples were submitted for identification at the 
University of Minnesota’s Center for Mass Spectrometry and Proteomics [179].  
 
2.2.11 Mass spectrometry of cellular LynA immunoprecipitates 
Peptide separations were performed on an Easy-nLC 1000 HPLC (Thermo Scientific) 
and loaded directly onto a 75 cm x 100-µm internal diameter fused silica PicoTip Emitter 
(New Objective, Woburn, MA), packed in-house with ReproSil-Pur C18-AQ (1.9 µm 
particle, 120 Å pore; Dr. Maish GmbH Ammerbuch, Germany) heated to 55°C. Peptide 
elution was performed using a tripartite gradient, decreasing the fraction of Buffer A 
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(0.1% formic acid in water) and increasing the fraction of Buffer B (0.1% formic acid in 
acetonitrile) at a flow rate of 300 nl/min (Step 1: 5-10% Buffer B over 5 min, Step 2: 10-
16% B over 40 min, and Step 3: 16-26% B over 5 min).  
 
The column was mounted in a nanospray source directly in line with an Orbitrap Fusion 
mass spectrometer (Thermo Scientific). Spray voltage was 2.1 kV in positive mode, and 
the heated capillary was maintained at 275 °C. The acquisition method combined two 
scan events corresponding to a full scan event and a parallel reaction monitoring (PRM) 
event targeting the singly-, doubly-, and triply-charged precursor ions of the three 
phosphorylated peptides without scheduling. The full scan event employed a m/z 380-
1500 mass selection, an orbitrap resolution of 60,000 (at m/z 200), a target automatic 
gain control (AGC) value of 4e5, and maximum fill times of 50 ms. The PRM event 
employed an orbitrap resolution of 30,000 (at m/z 200), a target AGC value of 5e4 with a 
maximum ion injection time of 54 ms. The precursor ion of each targeted peptide was 
isolated using an isolation window of 1.6 m/z. Fragmentation was performed with a HCD 
collision energy of 30% and MS/MS scans were collected using a scan range from 100-
1000 m/z. PRM data were collected in centroid mode. Data analysis was performed 
using manual integration using Thermo Xcalibur Qual Browser and Skyline [179, 180]. 
Peak searches were performed using PEAKS Studio X (Bioinformatics Solutions, 
Waterloo, Ontario). Experiments were run in triplicate, and the entire experiment was 
performed independently twice. Figures highlight one of these biological replicates, but 
the conclusions from the two sets of experiments are consistent. 
 
2.2.12 LynA kinase reactions and preparation for mass spectrometry analysis 
Purified recombinant Hck and GST-tagged LynA (Novus Biologicals, Centennial, CO and 
Thermo Fisher, respectively) were thawed and diluted in kinase buffer (25 mM Tris, pH 
7.5; 10 mM MgCl2; 100 uM Na3VO4) for reactions titrating LynA or keeping LynA fixed 
and titrating Hck. Kinase assays (40 µl total volume, containing 50-1000 ng LynA or 250 
ng LynA + 0-1000 ng Hck) were initiated by adding ATP to final concentration of 100 µM 
and then incubated at 30°C. An endpoint of 20 min was chosen based on a previous 
autophosphorylation study of recombinant Hck [38]. Reactions were stopped by adding 
40 µl quenching solution (1% formic acid, 99% acetonitrile) and then frozen on dry ice. 
Samples were lyophilized and reconstituted in a 25 µl total volume of 7 M urea; 2 M 
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thiourea; 0.4 M Tris, pH 7.5; 20% acetonitrile, 4 mM tris(2-carboxyethyl)phosphine 
(TCEP), and 5 mM EDTA and incubated at 37°C for 45 minutes. Iodoacetamide was 
added to a final concentration of 8 mM and incubated in the dark for 30 min. After this 
alkylation step, 50 µl water was added to reduce the urea concentration below 2 M. 
Trypsin was then added to each sample (1:80 trypsin: protein) and incubated at 37°C for 
18 h. Samples were dried and then desalted using a C18 stage-tip prior to the mass 
spectrometry run. 
 
2.2.13  Creation of LynAKO and LynBKO mice 
LynAKO was induced using two gRNAs to delete 77 bp encompassing portions of the 
unique LynA insert in mouse lyn exon 2 (5'-GAUCUCUCACAUAAAUAGUU-3') and the 
following intron 2 (5'-CCAUGCUCCGAUCCUACUGU-3'). NHEJ then induced a frame 
shift that resulted in a premature stop codon after amino-acid residue 77.  
 
LynBKO was induced using one gRNA (5'-GUUCGGUCAGUAUUACGUAC-3') to make a 
cut near the LynB splice site in exon 2. A donor oligonucleotide (5'-
AAAAGGAAAGACAATCTCAATGACGATGAAGTAGATTCGAAGACTCAACCAcTgCGT
AATACTGACCCAACTATTTATGTGAGAGATCCAACGTCCAATAAACAGCAAAGGCCA
GTAAG-3') was supplied to induce two single-nucleotide substitutions via HDR (lower-
case letters in the sequence) that ablated the LynB splice site and a SnaBI restriction 
site. gRNA’s were designed using CRISPOR.org [181] 
 
3-weeks old C57BL/6J female mice were purchased from The Jackson Laboratory and 
adapted to University of Minnesota animal facilities 3-4 days before the first hormone 
injection. The stud C57BL/6J male mice were obtained from the Jackson Laboratory 
directly. The recipient females CD-1 mice at 38-49 days old was purchased from the 
Charles River Laboratory. The animal protocols used for all mutant mice generation 
were approved by the Institutional Animal Care and Use Committee (IACUC). 
 
Microinjection of zygotes: The C57BL/6J females at 3-4 weeks old were superovulated 
by intraperitoneal injection of 5 IU pregnant mare serum gonadotropin, followed by 
injection of 5 IU human chorionic gonadotropin 48 hrs. later (both hormones from 
National Hormone & Peptide Program, Torrance, CA, USA), and they were immediately 
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crossed to C57BL/6J stud males. The next day, mouse zygotes were obtained from 
superovulated C57BL/6J females. For LynAKO, the zygotes were injected with mixture of 
30 ng/ul Cas9 protein, 3.5 ng/ul sgRNA each (2 sgRNA). For the LynB point mutation, 
the zygotes were injected with mixture of 30 ng/ul Cas9 protein, 3.5 ng/ul each of 2 
sgRNA, and 7 ng/ul of ssODN (120bp) donor as the point mutation template [182]. 
CRISPR reagents were designed by University of Minnesota Genome Engineering 
Shared Resources (GESR) and purchased from IDT. All CRISPR reagents were tested 
and validated on NIH 3T3 cells before the zygote injection. And all the CRISPR reagents 
were resuspended in the injection buffer (10 mM Tris-HCl, 0.25 mM EDTA, pH 7.4) for 
the zygote injection 
 
Toe DNA from the resulting pups was isolated using DNeasy Blood & Tissue Kit 
(Qiagen, Hilden, Germany) and subjected to an intermediate topo cloning step 
(Invitrogen, Carlsbad, CA) to insert PCR products into a plasmid for PCR sequencing 
(GeneWiz, South Plainfield, NJ) and digestion. A 500 bp segment in wild-type lyn 
encompassing the LynB splice site and the LynA unique insert was amplified using the 
following PCR primers: Forward 5’-acaaccgagatgtcctgct-3’ Reverse 5’-
agccagattatccctaaaatctctaca-3’. SnaBI (New England Biolabs, Ipswich, MA) cleavage of 
this product (recognition site TAC/GTA) generated two 250 bp fragments. In LynAKO a 
Cas9 double-cut deletion yields a shorter (~423 bp) PCR product that retains sensitivity 
to SnaBI cleavage. In LynBKO an HDR-induced mutation in the SnaBI site yields a 500 
bp PCR product insensitive to SnaBI. 
 
2.2.14 Tissue preparation and flow cytometry 
Spleens were excised from mice and cut into <1mm pieces before being digested for 30 
min in RPMI 2% FBS, 0.2 mg/mL collagenase type IV (Sigma-Aldrich, St. Louis, MO), 
37.5 ug/mL DNAse I (Worthington Biochemical, Lakewood, NJ), 1 U/mL Heparin D 
Sodium (Sigma-Aldrich, St. Louis, MO), 1 mM CaCl2 and 1 mM MgCl2. Single-cell 
suspensions were prepared by filtering digested spleens through 70 μm filters (Celltreat, 
Pepperell, MA). Antibody master mixes were prepared in PBS 2% FBS, 2mM EDTA. 
Antibodies used are enumerated in Table 2.2. For myeloid-cell-staining, cells were 
stained in 100 μL master mix at 37 °C for 30 min. For T and B cell panels, cells were 
stained at 4 °C for 30 min. Following surface staining for myeloid and B cell panels, cells 
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were fixed and permeabilized using BD Biosciences Fix/Perm kits according to 
manufacturer’s instruction. Intracellular staining of CD206 and Intracellular Ig occurred at 
4 °C overnight. For FoxP3 staining, cells were fixed and permeabilized using Tonbo 
Biosciences Transcription factor staining kit according to manufacturer’s instruction. 
Following intracellular staining, cells were washed with permeabilization buffer and 
resuspended in PBS 0.5% paraformaldehyde. Data was acquired using a BD Fortessa 




Marker Clone Source Color(s) 
XCR1 ZET Biolegend FITC, APC 
CD45 30-F11 Biolegend A700, BUV496 
PDCA-1 927 Biolegend BV421 
I-A/I-E M5/114.15.2 Biolegend BV510 
CD206 C068C2 Biolegend BV650 
CD64 X54-5/7.1 Biolegend BV711 
Ly6C HK1.3 Biolegend BV785 
TLR4 SA15-21 Biolegend Biotin 
TLR9 S18025A Biolegend FITC 
TLR2 CB225 Biolegend PE 
CD14 Sa14-2 Biolegend APC/Fire-750 
CD115 AFS98 Biolegend PE-Cy7 
CD38 90 Biolegend FITC, APC 
GL7 GL7 Biolegend PerCP-Cy5.5 
CD69 H1.2f3 Biolegend BV650 
CD138 281-2 Biolegend BV711 
CXCR5 L138D& Biolegend PE 
NK1 PK136 Biolegend BV421 
CD62L MEL-14 Biolegend BV510 
CD69 H1.2f3 Biolegend BV650 
PD-1 29F.1A12 Biolegend BV786 
IgM RMM-1 Biolegend PE-Cy7 
Ly6G 1A8 Tonbo Biosciences PerCP-Cy5.5 
CD80 16-10A1 Tonbo Biosciences PE 
CD86 P03.1 Tonbo Biosciences PE 
TCRβ H57-597 Tonbo Biosciences FITC, APC 
FoxP3 3G3 Tonbo Biosciences PerCP-Cy5.5, PE-Cy7 
CD44 IM7 Tonbo Biosciences PE-Cy7, PerCP-Cy5.5 
Ghost Dye Red 
780 
 Tonbo Biosciences  
CD16/32 2.4G2 Tonbo Biosciences  
CD11b M1/70 BD Biosciences BUV395, A700 
CD11c HL3 BD Biosciences BUV737 
IgD 11-26c.2a BD Biosciences BV786 
B220 RA3-6B2 BD Biosciences BUV395 
Intracellular Ig 550589 BD Biosciences PE 
CD4 GK1.5 BD Biosciences BUV395 
CD8a 53-6.7 BD Biosciences BUV737 
MerTK DS5MMER Invitrogen PE-Cy7 
Table 2.2: Antibodies used for flow cytometry  
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2.2.15 ex vivo splenocyte stimulation 
Spleens were excised from mice and placed in ice-cold RPMI, 2% FBS, 2 mM penicillin 
and streptomycin. Spleen tissue was mechanically disrupted using a 100-mm cell 
strainer (Corning) on a 50 ml tube, using a plunger of a 1 ml syringe. During and 
following processing of the spleen, strainers were flushed with ice-cold RPMI to acquire 
all cells. After processing, single-cell suspensions were counted and kept at 4˚C before 
proceeding with the in vitro stimulation. Stimulation and staining of cells were performed 
in 96-wells V-bottom plates (Nunc), using 2x106 cells per well in 50 μL RPMI. Cells were 
placed in a 5% CO2 37 °C incubator for 1 hr prior to treatment. CpG (IDT) and LPS 
(Invivogen) were diluted in RPMI 2-5% FBS and added by pipetting 50 ul of stimulus (in 
a 2-fold concentration) to the wells containing 50 ul of sample. 30 min. after stimulation, 
Brefeldin A and monensin (eBioscience) were added. 30 min. prior to the end of 
stimulation, Live/dead stain (Tonbo Biosciences) was added. Treatment was quenched 
at 4 hrs. by adding paraformaldehyde (PFA) to a final concentration of 1.6% and fixing at 
room temperature for 15 min. in the dark. Following fixation, cells were washed twice 
with BD Biosciences Fix/Perm diluent and by centrifuging at 0.4 x g for 5 min. and 
dumping supernatant. Cells were then mixed with staining master mix diluted in BD 
Biosciences Fix/Perm diluent overnight at 4 °C. Following intracellular staining, cells 
were washed twice with permeabilization buffer and resuspended in PBS, 0.5% PFA. 
Data was acquired using a BD Fortessa X-30 and analyzed using Flowjo. 
 
2.2.16 Anti-Nuclear Antibody Staining 
Kallestad HEp-2 (Bio-Rad, Cat. No. 30472) was used to detect Anti-Nuclear antibody 
staining according to the manufacturer’s instruction, modified to detect mouse IgG. 
Briefly, wells were incubated with 40 μL mouse serum, diluted 40x in phosphate-buffered 
saline + 1% Bovine-serum albumin, at room temperature for 20 min. After incubation, 
slides were washed in PBS for 10 minutes and incubated with 30 μL FITC-labeled goat-
anti-mouse IgG (Jackson ImmunoResearch, Cat. No. 115-095-164) diluted 200x and 
DAPI () diluted 10,000x for 20 min. at room temperature, followed by a 10 min. PBS 
wash. Slides were then mounted and coverslipped and viewed on an Olympus BX51 
fluorescent microscope equipped with a digital camera and DP-BSW software 
(Olympus). Images were quantified, pseudocolored, and merged using ImageJ software 





Kidneys and spleens were snap-frozen in optimal cutting temperature compound and 5-
μm sections were H&E stained. The presence and severity of nephritis was evaluated in 
a blinded fashion (as previously described [183]) by a pathologist. Scoring of 
glomerulonephritis and interstitial nephritis on a 0-3 scale (0=absent, 1=mild, 
2=moderate, 3=severe) for glomeruli was based on glomerular size, glomerular 
hypercellularity, and presence of glomerular sclerosis, and for interstitial disease was 
based on the degree of inflammatory infiltrate and alteration in tissue architecture. 
 
2.3 Footnotes 
Portions of this text were adapted from:  
 
Brian BF 4th, Guerrero CR, Freedman TS. Immunopharmacology and Quantitative 
Analysis of Tyrosine Kinase Signaling. Curr Protoc Immunol. 2020 Sep;130(1):e104. doi: 
10.1002/cpim.104. PMID: 32931655; PMCID: PMC7583487. 
 






CHAPTER 3:  Unique-region phosphorylation targets LynA for 




Phosphorylation of immunoreceptor tyrosine-based activation motifs (ITAMs) by Src-
family kinases (SFKs) is the first enzymatic step in the activation of an innate immune 
response during a pathogen encounter. Initiation of cell-activating signaling typically 
occurs within clusters of ITAM-coupled receptors such as FcγR [184] or the hemi-ITAM 
Dectin-1 [81, 185], nucleated by highly multivalent immunoglobulin-G-decorated 
pathogens or fungal cell-wall β-glucans respectively. Together, SFKs and 
phosphorylated ITAMs trigger activation of the tyrosine kinase Syk [18]. The SFKs and 
Syk then drive activation of membrane-proximal signaling through adaptor proteins, 
cytoskeleton-modulating proteins, such as the FAK/Pyk2 kinases and Paxillin, and Tec 
kinases, which activate second-messenger pathways via phosphoinositide 3-kinase 
(PI3K) and phospholipases C (PLC1/2). These early events ultimately lead to 
downstream signaling through Erk1/2 and other pathways [18]. As the byproducts of 
activated macrophages can be toxic (e.g. release of reactive oxygen species) and drive 
inflammation (e.g. release of tumor necrosis factor α), the responsiveness of innate 
immune cells is tightly regulated [62, 186-188]. 
Multiple mechanisms work together to tune the responsiveness of macrophages and 
other myeloid cells, including negative regulation by the phosphatases CD45 and CD148 
[61, 62, 189], cytoskeletal barriers to diffusion [74], signaling via immunoreceptor 
tyrosine inhibitory motifs (ITIMs) [190] and inhibitory ITAMs [191, 192], and degradation 
and sequestration of signaling molecules targeted for polyubiquitination by ubiquitin 
ligases [193, 194]. The SFKs, which in myeloid cells typically include Fgr, Fyn, two 
transcripts of Hck, and two splice forms of Lyn, may also have positive and negative 
functions [149, 151, 190, 195]. Layered onto the traditional positive- and negative-
regulatory roles of the SFKs, activated LynA (the longer of the two Lyn splice forms) is 
rapidly and specifically targeted for polyubiquitination and degradation, forming the basis 
of a signaling checkpoint that blocks spurious macrophage activation [22]. This 
checkpoint can be bypassed when LynA is upregulated, with LynA acting as a rheostat 
to tune macrophage sensitivity. For instance, LynA is transcriptionally upregulated when 
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macrophages are treated with interferon (IFN)-γ, and these primed cells have a lower 
threshold for SFK-mediated signaling [22]. The molecular mechanism that selectively 
targets LynA for polyubiquitination has not been elucidated previously. 
Unlike Dectin-1 and FcR signaling in macrophages, which are typically triggered in the 
context of pathogen-induced µm-scale clusters of receptors [22, 61, 62], mast-cell FcεR 
signaling has a low threshold for activation; small or even monovalent antigen-IgE 
complexes can induce a signaling response in the context of a cell-particle interaction 
[196-198]. Supporting this more permissive signaling function, the binding dynamics of 
Syk with FcεRI in mast cells is unaffected by the size of receptor aggregates [199]. Like 
macrophages, mast cells express LynA, and the disparity in the receptor sensitivity of 
these two cell types has not previously been explained. 
This chapter describes the mechanism by which activated LynA is selectively recognized 
and rapidly degraded, thereby tuning both its steady-state expression and its activation 
kinetics in a cell-specific manner. To reveal the requirements for LynA degradation, we 
synchronized receptor-independent SFK activation using the designer inhibitor 3-IB-PP1 
[70, 200, 201], which specifically inhibits a variant of the SFK-inhibitory kinase Csk 
(CskAS) [22, 70, 71]. Csk is responsible for phosphorylating a key inhibitory tyrosine in 
the C-terminal tail of all the SFKs. Inhibiting CskAS with 3-IB-PP1 disrupts the dynamic 
equilibrium between Csk and the phosphatases CD45 and CD148, which 
dephosphorylate the inhibitory tyrosine, leading to rapid and robust SFK activation [202, 
203]. Using this model, we discovered that 3-IB-PP1-induced SFK activation leads to the 
phosphorylation and activation of the E3 ubiquitin ligase c-Cbl [87, 204] and the 
preferential polyubiquitination and degradation of LynA in macrophages, but it was not 
clear whether these two events were linked. Using knockout and overexpression models 
coupled with quantitative targeted mass spectrometry and analyses of protein 
abundance and cell signaling, we now demonstrate that c-Cbl controls the steady-state 
expression of LynA and mediates its rapid degradation upon activation in macrophages. 
LynA is targeted by c-Cbl in response to phosphorylation of tyrosine 32 (Y32) within the 
LynA unique region mediated by LynA, LynB or the shorter isoform of Hck. This 
recognition mode is distinct from the slower-phase action of c-Cbl and other E3 ligases 
on LynB and the other SFKs [22, 96, 205] . Finally, we have discovered that the LynA 
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checkpoint is cell-specific. In mast cells, which express very little c-Cbl but abundant 
Cbl-b, LynA is not rapidly degraded upon activation, a function that can be rescued by 
induced overexpression of c-Cbl. The differential regulation of c-Cbl and LynA may drive 






3.2.1 c-Cbl mediates steady-state and activation-induced degradation of LynA in 
macrophages 
Our lab reported previously that activated LynA is rapidly polyubiquitinated and 
degraded in CskAS macrophages treated with the CskAS inhibitor (SFK activator) 3-IB-
PP1 [22]. To identify the E3 ubiquitin ligase that mediates this degradation, we tested the 
functions of c-Cbl and Cbl-b, known modulators of ITAM signaling in both adaptive and 
innate immune cells [190, 193, 206]. We first used small interfering (si)RNAs to knock 
down the expression of c-Cbl and Cbl-b. CskAS BMDMs were transfected with non-
targeting control RNA (ctrl) or with siRNA constructs targeting c-Cbl or Cbl-b. Rested 
transfectants were then treated with 3-IB-PP1 to induce SFK activation. Immunoblots of 
siRNA-transfected BMDM lysates (Figure 3.1A) showed modest but specific knockdown 
of c-Cbl (70% reduced) and Cbl-b (60% reduced) proteins, without a corresponding 
increase in c-Cbl expression as a consequence of Cbl-b knockdown (Figure 3.1B).  
 
Loss of c-Cbl, but not Cbl-b, resulted in impaired degradation of LynA in the first few 
minutes of 3-IB-PP1 treatment and increased steady-state expression of LynA protein 
(Figure 3.1C,D). To further confirm the importance of c-Cbl, we bred CskASCbl-/- and 
CskASCblb-/- mice from existing Cbl-/- [168] and Cblb-/- [91] strains and used these mice to 
generate CskASc-Cbl-/- and CskASCbl-b-/- bone-marrow-derived macrophages (BMDMs). 
Immunoblots of whole-cell lysates show the loss of expression of c-Cbl and Cbl-b in 
CskASc-Cbl-/- and CskASCbl-b-/- BMDMs, respectively, compared to CskAS BMDMs (Figure 
3.2A-B). Resting (unprimed) BMDMs were then treated with 3-IB-PP1 to induce 
activation of the SFKs (Figure 3.2A). 
 
As in the cbl-knockdown experiments, knockout of c-Cbl profoundly impaired the 
degradation of activated LynA in the first few minutes of 3-IB-PP1 treatment, with LynA 
levels remaining at 100% after 1 min of exposure to 3-IB-PP1 in CskASc-Cbl-/- BMDMs 
compared to 60% in CskAS BMDMs (Figure 3.2C). CskASc-Cbl-/- BMDMs also expressed 
3-fold more LynA protein than CskAS at steady state (Figure 3.2D). The impaired 
degradation and increased steady-state LynA expression together resulted in 6- to 8-fold 




Figure 3.1. siRNA knockdown of c-Cbl expression in macrophages leads to 
steady-state upregulation and delayed degradation of LynA protein. 
(A) Immunoblots showing LynA, c-Cbl, and Cbl-b protein in CskAS BMDMs transfected 
with non-targeting RNA (ctrl) or with siRNA constructs targeting Cbl or Cblb mRNA. 
Rested cells were treated with 3-IB-PP1 for the indicated times; β-Actin is shown as a 
loading control. (B–D) Quantification of relative c-Cbl, Cbl-b, and LynA protein, corrected 
for total protein content (TPS). SEM, n = 3. (B) Quantification of c-Cbl protein (red) and 
Cbl-b protein (blue), reported relative to their expression in ctrl BMDMs (dotted line). 
Remaining expression of the other Cbl family member is shown in gray. (C–D) 
Quantification of LynA, reported relative to the steady-state level in each siRNA 
condition (C) or relative to the level in the ctrl sample at steady state (D) in ctrl (black 
dotted), c-Cbldown (red), and Cbl-bdown (blue) samples. Sig. from ANOVA2-Tukey: [c-
Cbldown vs. ctrl, black asterisks], [c-Cbldown vs. Cbl-bdown, blue asterisks]; ****p<0.0001, 






Figure 3.2. Loss of c-Cbl expression in macrophages leads to steady-state 
upregulation and delayed degradation of LynA protein. (A) Immunoblots showing 
LynA and Cbl protein in CskAS, CskASc-Cbl-/-, and CskASCbl-b-/- BMDMs treated with 3-IB-
PP1 for the indicated times. Interdomain-B-phosphorylated SykpY352 [17, 207, 208], an 
SFK target and prerequisite for Syk activation, is shown as a control for 3-IB-PP1-
initiated signaling; total Erk1/2 is shown as a loading control. (B-D) Densitometry 
quantification of relative levels of Cbl and LynA protein, corrected for total protein 
content using REVERT Total Protein Stain (TPS). (B) Quantification of c-Cbl (red) and 
Cbl-b (blue) in CskASc-Cbl-/- and CskASCbl-b-/- BMDMs relative (rel.) to their steady-state 
levels in CskAS BMDMs (dotted line). Expression of the other Cbl family member is 
shown in gray. Error bars reflect the standard error of the mean (SEM), n=4 from three 
CskASc-Cbl-/- mice and n=3 from two CskASCbl-b-/- mice. (C-D) Quantification of LynA 
relative to the steady-state level in each genotype (C) or relative to the steady-state level 
in CskAS BMDMs (D). SEM, n=8 for CskAS, n=5 from three CskASc-Cbl-/- mice, n=3 from 
two CskASCbl-b-/- mice. The significance (Sig.) from two-way ANOVA (ANOVA2) with 
Tukey’s multiple comparison test (-Tukey) are as follows: [CskASc-Cbl-/- vs. CskAS black 
asterisks], [CskASc-Cbl-/- vs. CskASCbl-b-/-, blue asterisks]; **** P<0.0001, *** P=0.0001-
0.0005, * P=0.0171-0.0459. Other pairs ns. Note: some of the error bars are smaller 




The effects of c-Cbl knockdown are blunted relative to CskASc-Cbl-/- BMDMs, likely due 
to incomplete knockdown. As in the knockout experiments, LynA degradation in c-Cbl 
siRNA BMDMs was not fully eliminated but occurred on a much slower timescale, similar 
to the degradation of the other SFKs [22] (Figure 3.1C-D). Without c-Cbl upregulation in 
Cbl-b-knockdown BMDMs, we saw no increase in the LynA degradation efficiency or 
decrease in the steady-state level of LynA protein. 
 
Although it has been reported previously that c-Cbl and Cbl-b have some redundant 
functions [92, 209], we were unable to detect any role for Cbl-b in suppressing the 
steady-state level or promoting the activation-induced degradation of LynA. Upon 
treatment for 1 min with 3-IB-PP1, LynA was 81% reduced in CskASCbl-b-/- compared to 
60% in CskAS BMDMs (Figure 3.2C). Although not statistically significant, steady-state 
expression of LynA was slightly depressed in CskASCbl-b-/- BMDMs (Figure 3.2D). This 
increase in LynA degradation may be explained by a compensatory upregulation of c-
Cbl protein expression in CskASCbl-b-/- BMDMs (Figure 3.2B). 
 
In the above experiments activating Syk phosphorylation was used as a control for 3-IB-
PP1-induced SFK signaling. Notably, Syk phosphorylation is enhanced in 3-IB-PP1-
treated CskASc-Cbl-/- BMDMs, consistent with the higher expression level and longer half-
life of LynA protein (Figure 3.2A). Syk phosphorylation is also enhanced in 3-IB-PP1-
treated CskASCbl-b-/- BMDMs, but this is likely due to the direct role of Cbl-b on Syk 
inhibition [210]. Activating phosphorylation of Erk1/2, a downstream signaling protein, is 
also complicated by the functions of the E3 ligases themselves. Erk phosphorylation in 
3-IB-PP1-treated CskASc-Cbl-/- BMDMs is impaired (Figure 3.3), likely due to the loss of 
the adaptor function of c-Cbl in PI3K signaling [211, 212]. In 3-IB-PP1-treated CskASCbl-
b-/- BMDMs, Erk1/2 phosphorylation, like Syk phosphorylation, is enhanced, again likely 
due to the negative-regulatory role of Cbl-b for Syk and other upstream signaling 
intermediates. 
 
Overall, we conclude that c-Cbl is solely responsible for LynA-specific rapid degradation, 
whereas other E3 ubiquitin ligases can complement the canonical SFK-binding and -
polyubiquitinating function of c-Cbl [96, 205], which mediates slower degradation of LynA 






Figure 3.3. Paradoxical changes in Erk1/2 phosphorylation in Cbl-deficient cells 
obscure the contribution of LynA to signaling. Immunoblot showing impaired 
activating phosphorylation of Erk1/2pT202/pY204 (pErk1/2) in CskASc-CblKO BMDMs and 
enhanced Erk phosphorylation in CskASCbl-bKO BMDMs compared to CskAS BMDMs 




3.2.2 A tyrosine residue in the unique-region insert of LynA is required for its 
rapid degradation 
Susceptibility to rapid, activation-induced degradation differentiates LynA from the splice 
variant LynB and the other abundant SFKs in macrophages, Hck (59 and 56 kDa 
transcripts) and Fgr [151], which are degraded >10-fold more slowly than LynA during 3-
IB-PP1 treatment [22]. The SFK FynT (Fyn) has also been reported to play an important 
role in macrophage inflammatory signaling [195]. We now confirm that, like Hck, Fgr, 
and LynB, macrophage Fyn is long-lived during 3-IB-PP1 treatment (Figure 3.4A), 
although we have been unable to detect Fyn activation in response to 3-IB-PP1 [22]. We 
also tested degradation of transfected LynA in comparison with endogenous Fyn and 
Lck in Jurkat T cells cotransfected with c-Cbl and a membrane-localized variant of CskAS 
(memCskAS) [70], which sensitizes Jurkat cells to 3-IB-PP1, enabling synchronized SFK 
activation. As in macrophages, LynA is rapidly degraded in Jurkat cells treated with 3-IB-
PP1, in contrast to longer-lived Lck [70] and Fyn (Figure 3.4B). This highlights the 
unique susceptibility of LynA to rapid, c-Cbl-mediated degradation and suggests that cell 
types, such as T cells, that do not express Lyn may lack an analogous, rapid off-switch 







Figure 3.4. LynA is degraded more rapidly than Fyn and Lck during 3-IB-PP1 
treatment. Immunoblots and quantification of SFK levels over the course of 3-IB-PP1 
treatment. In both panels total Erk1/2 protein is shown as a loading control. Quantified 
values are corrected for total protein content (TPS) and reported relative to the steady-
state level of each SFK. (A) Levels of Fyn (dark orange), Hck (light orange), LynA 
(black), and LynB (brown, dotted) protein in 3-IB-PP1-treated CskAS BMDMs. SEM, n=3. 
Sig. from ANOVA2-Tukey: [Fyn vs. LynA, dark orange asterisks], [Hck vs. LynA, light 
orange asterisks], [LynB vs. LynA, brown asterisks]; **** P<0.0001, *** P=0.0006-
0.0009, ** P=0.0034. (B) Levels of Fyn (dark orange) and Lck (slate) and His6V5-tagged 
LynA (black) in 3-IB-PP1-treated Jurkat T cells cotransfected with memCskAS and c-Cbl. 
SEM, n=4. Sig. from ANOVA2-Tukey: [Lck vs. LynA, slate asterisks], [Fyn vs. LynA, dark 




To determine which residues in the LynA protein mediate the unique interaction with c-
Cbl, we undertook a mutational analysis. We were, however, unable to achieve 
expression of LynA variants in CskAS or CskASLyn-/- BMDMs [22] by transfection, Amaxa 
nucleofection, or lentiviral transduction, likely due to toxicity of overexpressed Lyn. As an 
alternative approach, we expressed LynA ectopically in Jurkat cells by transient 
cotransfection of His6V5-tagged variants of Lyn along with a Cbl-family ligase and 
memCskAS. As a proof of principle for this model, we first transfected Jurkat cells with 
wild-type LynA, memCskAS, and either empty vector (ctrl), c-Cbl, or Cbl-b plasmid DNA 
(Figure 3.5A), which increased c-Cbl expression 3-fold and Cbl-b 25-fold, respectively, 
over endogenous levels (Figure 3.5B). Overexpressing one Cbl family member did not 
affect the abundance of the other. Phosphorylation of Erk1/2, via the combined effects of 
transfected LynA and endogenous Lck, demonstrates that 3-IB-PP1 was applied to all 
transfectants (Figure 3.5A). As predicted, c-Cbl overexpression in Jurkat cells increased 
the rate of LynA degradation (30% depletion after 5 min treatment with 3-IB-PP1 in c-
Cbl-overexpressing Jurkat cells compared to no detectable depletion in either ctrl or Cbl-
b-overexpressing cells) (Figure 3.5C). This observation is consistent with the knockout 
and siRNA experiments in BMDMs, demonstrating that Jurkat cells, which do not 







Figure 3.5. Unique-region tyrosine 32 is required for activation-induced 
degradation of LynA. (A) Immunoblots of Jurkat cells cotransfected with His6V5-tagged 
LynA, Myc-tagged memCskAS, and either empty vector (ctrl), c-Cbl, or Cbl-b and treated 
with 3-IB-PP1. Phosphorylated Erk1/2pT202/pY204 (pErk1/2) is shown as a qualitative 
control for 3-IB-PP1-initiated signaling from the combined effects of transfected LynA 
and endogenous Lck. As expect Total Erk1/2 is shown as a loading control. (B-C) 
Quantification of relative Cbl and V5-tagged LynA protein, corrected for total protein 
content (TPS). SEM, n=4. (B) Quantification of overexpressed c-Cbl (orange) and Cbl-b 
(dark blue) relative to endogenous (ctrl) levels (dotted line). Endogenous expression of 
the other Cbl family member in each condition is shown in gray. (C) Quantification of 
LynA protein during 3-IB-PP1 treatment relative to the steady-state level for transfections 
of empty-vector ctrl (black dotted), c-Cbl (orange), or Cbl-b (dark blue). Sig. from 
ANOVA2-Tukey: [c-Cbl vs. ctrl, black asterisks], [c-Cbl vs. Cbl-b, blue asterisks]; ** 
P=0.0092, * P=0.0270-0.0102. Other pairs ns. (D) N-terminal amino-acid sequences of 
mouse LynA and LynB [146, 213], including the 21 amino-acid unique-region insert of 
LynA, highlighting residues Y32 (olive), T27 (light gray), and K40 (dark gray). (E) 
Immunoblots of 3-IB-PP1-treated Jurkat cells cotransfected with c-Cbl, Myc-tagged 
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memCskAS, and His6V5-tagged Lyn constructs, including wild-type LynA, LynAY32A, LynB, 
LynAK40R, LynAT27A, or LynAY32F. (F) Quantification of protein levels of V5-tagged LynA 
(black dotted), LynAY32A (olive), LynB (teal dotted), LynAK40R (dark gray), LynAT27A (light 
gray), and LynAY32F (orange) over the course of 3-IB-PP1 treatment, corrected for total 
protein content (TPS) and reported relative to the steady-state level for each Lyn variant. 
SEM, n=7 for LynA, n=4 for LynAY32A and LynB; n=3 for LynAK40R, LynAT27A, and 
LynAY32F. Sig. from ANOVA2-Tukey: [LynAY32A vs. LynA, olive asterisks], [LynB vs. LynA, 
teal asterisks], [LynAY32F vs. LynA, orange asterisks], [LynAK40R vs. LynAY32A, dark gray 
asterisks], [LynAT27A vs. LynAY32A, light gray asterisks], [LynB vs. LynAK40R, P=0.013, 
0.01], [LynB vs. LynAT27A, P<0001], [LynY32F vs. LynAK40R, P=0.012, 0.0157], [LynT27A vs. 
LynAY32F, P<0.0001], [LynY32A vs. LynAK10R, P<0.0001]; **** P<0.0001, *** P=0.0006, * 




LynB, which lacks a 21 amino-acid insert found in the unique region of LynA (Figure 
3.5D), was less efficiently degraded (10% depleted after 5 min treatment with 3-IB-PP1) 
than LynA (40% depleted after 5 min) in c-Cbl- and memCskAS-cotransfected Jurkat cells 
(Figure 3.5E-F). Again, these data mirror our findings in CskAS BMDMs [22] and confirm 
that the unique susceptibility of LynA to rapid degradation is preserved in the Jurkat 
model. We hypothesized that the targeting site in LynA must lie within the unique-region 
insert (residues 23-43), absent in LynB [146, 213], which contains a tyrosine residue 
reported to be phosphorylated in cancer cells [Y32; 150, 214], a predicted threonine 
phosphorylation site [T27; NetPhos 3.1, 215] and predicted lysine ubiquitination site 
[K40; UbPred, 216] (Figure 3.5D). 
 
Substituting Y32 with either A or F blocked the rapid degradation of LynA (Figure 3.5E), 
reducing the depletion after 5 min treatment with 3-IB-PP1 from 40% (LynA) to 10% 
(LynAY32A) or 8% (LynAY32F), levels indistinguishable from LynB (10%) (Figure 3.5E-F). 
Substitution of Y32 did not alter the membrane localization of a unique-region construct 
at steady state or after 3-IB-PP1 treatment (Figure 3.6A). Neither the predicted 
ubiquitination site mutation (LynAK40R) nor the threonine phosphorylation site mutation 
(LynAT27A) significantly affected the rate of LynA degradation (Figure 3.5F). 
As in BMDMs, the efficiency of Lyn degradation correlated with its steady-state 
expression in Jurkat cells. LynB is 2-fold and LynAY32A 3-fold more highly expressed than 
wild-type LynA, LynAK40R, or LynAT27A at steady state, resulting in 3- to 4-fold more 
protein remaining after 20 min treatment with 3-IB-PP1. 
 
Overall, we conclude that the unique tyrosine residue Y32 in the LynA insert flags LynA 
for rapid, c-Cbl-mediated degradation and that this mechanism both determines the half-







Figure 3.6. The unique regions of LynA, LynB, and LynAY32A are membrane-
localized in resting and 3-IB-PP1-treated cells. Representative epifluorescence 
images of GFP-tagged unique-region (UR) constructs of LynA, LynB, and LynAY32A, 





3.2.3 Phosphorylation on tyrosine 32 targets activated LynA for polyubiquitination 
Although phosphorylated LynAY32 has been found in liver and mammary tumor cells 
[150, 214], it has been unclear whether this posttranslational modification is functionally 
relevant in hematopoietic cells and whether Y32 is phosphorylated as a consequence of 
SFK activation. To probe for Y32 phosphorylation, we performed quantitative targeted 
liquid chromatography-coupled tandem mass spectrometry (LC-MS/MS) analysis of 
LynA immunoprecipitated from resting and 3-IB-PP1-treated BMDMs. We expected 
phosphorylation at this site to be transient due to the rapid degradation of LynA, and so 
we used a two-pronged approach to enrich potential Y32-phosphorylation: (i) CskASc-
Cbl+/- BMDMs were used to slow the rate of LynA polyubiquitination, and (ii) 3-IB-PP1 
was applied as a 15 second pulse treatment. At this early time point, all SFKs are 
expected to be activation-loop phosphorylated, with only 20% of all LynA 
polyubiquitinated, as we have observed in wild-type BMDMs [22]. 
 
Lysates from resting and 3-IB-PP1-treated BMDMs, normalized for total protein content, 
were subjected to immunoprecipitation using a LynA-specific antibody [22] (Figure 
3.7A). Although some polyubiquitinated LynA species were generated, LynA was largely 
nonubiquitinated, as expected in CskASc-Cbl+/- BMDMs pulse-treated with 3-IB-PP1. 
Bands from a Coomassie-stained gel containing nonubiquitinated and polyubiquitinated 
LynA were excised, normalized for protein content, and spiked with reference amounts 
of isotope-labeled control peptide corresponding to the tryptic fragment of Lyn 
encompassing pY32. These samples were then subjected to in-gel trypsin digestion and 
analyzed by LC-MS/MS. Peptides corresponding to phosphorylated and 
unphosphorylated LynA Y32, including the isotope-labeled standard, were detected in 
nonubiquitinated and polyubiquitinated LynA species from 3-IB-PP1-treated cells 
(Figure 3.7C). We were able to resolve phosphorylated and unphosphorylated Y32 
peptide and other potential phosphorylated species within the same tryptic peptide via 
their elution profiles: pY32 peptide coeluted with its isotopically labeled counterpart and 
these were clearly separated from unphosphorylated and threonine-phosphorylated 
species (Figure 3.8A-F). The identity of each peptide was assigned via the MS/MS 




Figure 3.7. Tyrosine 32 is a site of activation-induced phosphorylation in 
macrophages. (A) Blots showing immunoprecipitation of LynA from CskASc-Cbl+/- 
BMDMs with (+) or without (-) a 15 second treatment with 3-IB-PP1. Nonubiquitinated 
(nonUb) and polyubiquitinated (polyUb) LynA species in whole-cell and immunodepleted 
lysate (Lysw and Lysdep, respectively) and IP samples are shown. (B) Total-protein-
stained gel showing regions excised for LC-MS/MS analysis of polyUb LynA (higher 
boxes) and nonUb LynA (lower boxes); box colors correspond to the bar graphs below. 
Total IP protein content was quantified by applying densitometry to the whole lane and 
assigned mass values using a BSA standard curve. Normalized amounts (based on the 
total IP protein content) were spiked with 125 fmol isotope-labeled control peptide 
(pY32*pep) corresponding to the phosphoY32-containing tryptic fragment of LynA and 
subjected to in-gel trypsin digestion and LC-MS/MS. (C) Tryptic peptides corresponding 
to IP-derived unphosphorylated-Y32-containing LynA peptide (Y32pep), IP-derived 
phosphorylated-Y32-containing LynA peptide (pY32pep), and added pY32*pep were 
quantified by using parallel reaction monitoring (PRM) to trigger MS/MS spectra for 
peptide parent ions, 687.3267 and 690.3336 m/z, respectively. Extracted ion 
chromatograms (XICs) were derived from Skyline for MS/MS fragment ions 
corresponding to y and b ionic fragments from Y32, pY32, and pY32* peptides and used 
to quantify the ratios of pY32pep:pY32*pep or pY32pep:Y32pep. Ion-annotated 
Representative XICs are shown in Figure 3.8. Assignments of peptide species to specific 
phosphorylation states are shown in Figure 3.8. Detection of phosphorylated species in 
IP samples is shown in Figure 3.8.. (D-E) Quantitative analysis of Y32 phosphorylation in 
resting and 3-IB-PP1-treated BMDMs, including nonUb species from resting BMDMs 
(blue dotted), nonUb species from 3-IB-PP1-treated BMDMs (orange), and polyUb 
species from 3-IB-PP1-treated BMDMs (red). Although we analyzed a gel fragment that 
would contain any polyUb species in resting BMDMs (gray dotted), this species was 
sufficiently rare as to be unquantifiable. Error bars represent the standard deviation 
(stdev) of n=3 technical replicates. Data from two biological replicates are shown side by 
side. (D) Quantification of pY32pep in nonUb species from resting vs. 3-IB-PP1-treated 
BMDMs normalized to the total protein content of each IP. This analysis relies on an 
assumption equal amounts of total LynA in each sample, so this analysis was used only 
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to nonUb samples, which were roughly equally abundant in resting and 3-IB-PP1-treated 
BMDMs. Sig. from two-tailed t tests for each experiment: [nonUb resting vs. nonUb 3-IB-
PP1-treated, asterisks]; **** P<0.0001. (E) Quantification of pY32pep in nonUb vs. polyUb 
species in 3-IB-PP1-treated BMDMs normalized to amount of unphosphorylated Y32 pep. 
Sig. from two-tailed t tests for each experiment: [nonUb resting vs. nonUb 3-IB-PP1-





Figure 3.8. PRM chromatograms and spectra for unphosphorylated and 
phosphorylated LynA Y32 tryptic peptides.(A) PRM chromatograms illustrating 
resolution of synthetic phosphorylated and unphosphorylated peptides (top and middle 
panels), resolution of pY32 and synthetic threonine-phosphorylated (pT) species (middle 
panel), and coelution of unlabeled pY32pep with isotope-labeled pY32*pep (middle and 
bottom panels). Species detected in LynA IPs (Y32 pep, pY32 pep, and pY32*pep) are 
indicated in bold type, phosphorylation sites are shown in red, and the isotope-labeled 
proline residue is shown in blue. (B–F) MS/MS spectra for synthetic peptides 
corresponding to tryptic peptides containing LynA Y32. The expected fragmentation 
pattern for each is indicated with phosphoions labeled in red/bold and isotope-labeled 
ions labeled in blue/bold. (B) MS/MS for Y32pep run at 647.3435 m/z. (C) MS/MS for 
pY32pep run at 687.3267 m/z, with highlighted fragment ions from phosphoY32. (D) 
MS/MS for pT30pep run at 687.3267 m/z, with highlighted fragment ions from 
phosphoT30. (E) MS/MS for pT37pep run at 687.3267 m/z, with highlighted fragment ions 
from phosphoT37. (F) MS/MS for pY32*pep run at 687.3267 m/z, with highlighted 
fragment ions from phosphoY32 and the isotope-labeled proline residue.  
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In the LynA immunoprecipitates the tryptic peptide spanning residue 32 was 
phosphorylated at Y32 but not at T30 or T37. Search results in the PEAKS software 
package did not yield any matches for single or double threonine phosphorylation in 
combination with pY32, enabling complete analysis of LynA Y32 phosphorylation using 
an isotope-labeled pY32 peptide as the sole reference. Molar quantities of 
phosphorylated and unphosphorylated LynA Y32 peptide were derived by integrating the 
appropriate extracted ion chromatogram (XIC) peaks and correcting these values using 
standard curves with known molar ratios of unlabeled and isotope-labeled pY32 
peptides. For some analyses, a second calibration curve was used to determine the 
molar quantities of unphosphorylated Y32 peptide. 
 
We detected LynA Y32 phosphorylation in 3-IB-PP1-treated BMDMs in two independent 
experiments. After immunoprecipitation and sample processing, pY32 was 6- to 12-fold 
enriched in nonubiquitinated Lyn from 3-IB-PP1-treated BMDMs relative to resting 
BMDMs (Figure 3.7D). LynA Y32 is therefore a site of inducible phosphorylation 
following activation of SFKs in primary macrophages. In resting BMDMs the vast 
majority of LynA is inactive [22] and therefore may be protected from bulk degradation 
by lack of phosphorylation of this site. Phosphorylated Y32 peptide was, however, 
detectable at low levels in resting BMDMs, supporting a model in which the bulk 
differences in the steady-state levels of LynA protein in cells lacking c-Cbl expression 
(Figure 3.2) are attributable to mass action, driven by degradation of small quantities of 
basally active LynA. 
 
Although LynA Y32 phosphorylation was detected in activated but nonubiquitinated 
LynA, this effect was even greater in polyubiquitinated LynA, which was 6.0- to 6.4-fold 
enriched in Y32 phosphorylation relative to nonubiquitinated LynA (Figure 3.7E). It is 
therefore likely that phosphorylation of LynA Y32 is an early consequence of SFK 




3.2.4 Activated LynA induces its own degradation in trans 
In macrophages and other hematopoietic cells SFKs are the first kinases to be activated 
upon ITAM-coupled receptor engagement, phosphorylating intracellular ITAMs, ITAM-
associated Syk or Zap-70 [17, 207], and integrin-associated FAK or Pyk2 [18, 217]. We 
have reported that Syk and FAK are phosphorylated on activating tyrosine residues in 
CskAS BMDMs treated with 3-IB-PP1 [22]. To test whether these downstream kinases 
might participate in negative feedback leading to LynA degradation, we treated CskAS 
macrophages with competitive inhibitors of Syk [218], FAK/Pyk2 [219], or the SFKs 
themselves [220] in combination with 3-IB-PP1. As controls for on-target effects, we 
demonstrated that Erk1/2 and SFK activation-loop phosphorylation were blocked in 
samples cotreated with the pan-SFK inhibitor PP2, that Erk1/2 but not SFK activation-
loop phosphorylation was blocked in samples cotreated with the Syk inhibitor BAY-61-
3606, and that Paxillin phosphorylation was blocked in samples cotreated with the 
FAK/Pyk2 inhibitor PF-431396 (Figure 3.9A). SFK inhibition via PP2 treatment 
abrogated LynA degradation (Figure 3.9A-B). In contrast, LynA degradation was 
unaffected by Syk or FAK/Pyk2 inhibition. Together these data suggest neither Syk nor 
FAK/Pyk2 (or any off-target kinases inhibited by BAY-61-3606 and PF-431396) 
participates in a negative-feedback loop leading to LynA degradation, suggesting that 
the only upstream kinases, the SFKs, might phosphorylate LynA Y32 directly in cis or 







Figure 3.9. Syk, FAK, and Pyk2 kinase activities are not necessary for the rapid 
degradation of LynA. (A) Immunoblots showing expression of endogenous LynA 
protein in CskAS BMDMs treated with 3-IB-PP1 only or cotreated with 3-IB-PP1 and the 
Syk inhibitor BAY 61-3606, the SFK inhibitor PP2, or the FAK/Pyk2 inhibitor PF-431396. 
Activated signaling proteins including SFKs (pSFKact, activation-loop-phosphorylation 
corresponding to SrcpY416), pErk1/2, and PaxillinpY118 (pPaxillin) are shown as controls for 
inhibitor function; β-Actin and total Erk1/2 are shown as loading controls. (B) 
Quantification of LynA protein during 3-IB-PP1 treatment only (black dotted) or with the 
inhibitors BAY 61-3606 (iSyk, light olive), PP2 (iSFK, red), or PF-431396 (iFAK/Pyk2, 
green), corrected for total protein content (TPS) and reported relative to the steady-state 
level of LynA. SEM, n=3. Sig. from ANOVA2-Tukey: [+PP2 vs. 3IB only, asterisks]; **** 
P<0.0001. Other pairs ns. 
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To investigate the role of LynA kinase activity in its degradation, we turned again to 
Jurkat-cell transfections, testing three functionally impaired variants of LynA: LynAT410K, 
which has disrupted substrate recognition [221], and LynAY397F, which lacks the key 
autophosphorylation site that stabilizes the kinase active state and interacts with c-Cbl 
[31, 96, 202]. To minimize interference from T-cell endogenous SFKs, we used Lck-
deficient JCaM1.6 cells; previous work has shown that endogenous Fyn does not 
independently activate the TCR signaling pathway in this cell line [171, 172]. When 
transfected into JCaM1.6 cells along with memCskAS and c-Cbl, only catalytically 
competent His6V5-tagged LynA was subject to rapid, 3-IB-PP1-induced degradation 
(Figure 3.10A); we did not detect degradation of the substrate-binding-impaired variant 
(T410K) or the activation-loop-mutated variant (Y397F). Zap-70 phosphorylation was 
only visible in JCaM1.6 cells transfected with wild-type LynA, demonstrating the 
functional impairment of LynAT410K and LynAY397F. 
 
We then transfected the same variants of LynA into Lck-expressing Jurkat cells (Figure 
3.10B). The presence of phosphorylated Zap-70 in all transfections demonstrates the 
expected activation of endogenous Lck in response to 3-IB-PP1 [70, 171, 222, 223]. 
Activated Lck, however, was unable to induce degradation of LynA, with no detectable 
loss of either catalytically-impaired variant (Figure 3.10C). To ensure that the substrate-
binding and conformational elements altered in the T410K and Y397F variants did not 
affect our results, we confirmed that the active-site mutant LynAK275R was similarly 
resistant to 3-IB-PP1-induced degradation (Figure 3.11). 
 
We wondered whether mutation of Y32 disrupts the interaction between LynA and c-Cbl. 
To investigate this, we transfected Jurkat cells with memCskAS and c-Cbl, along with V5-
tagged constructs for LynA, LynB and LynAY32A. We then treated these cells with 3-IB-
PP1 to induce SFK and c-Cbl activation, and performed an immunoprecipitation for V5 
(Figure 3.12). When we quantified the amount of c-Cbl co-immunoprecipitated with each 
Lyn construct, we saw that c-Cbl-association with Lyn increased upon 3-IB-PP1-
treatment as expected (Figure 3.12A). However, we saw minimal differences in the 
ability of LynA, LynB, or LynAY32A to co-immunoprecipitate c-Cbl (Figure 3.12C). Lyn 
can interact with c-Cbl through multiple compensatory mechanisms. We wondered 
whether Lyn-SH3 domain binding to poly-proline motifs, Lyn kinase activity, and Lyn 
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activation loop phosphorylation were providing compensatory mechanisms that might 
obscure the effect of Y32 phosphorylation. To investigate this we made triple mutants, 
W100A/ T410K/ Y397F, of LynA, LynB and LynAY32A that would block the ability of Lyn’s 
SH3 domain to interact with c-Cbl  (W100A [224]), through substrate binding (T410K) or 
through activation loop phosphorylation (Y397F). We also co-transfected in LynAY32A, 
without a V5 tag to provide the necessary kinase activity required for c-Cbl activation 
(Figure 3.12B). Introduction of these three mutations had a stark effect on c-Cbl binding 
to all Lyn variants (Figure 3.12C). Although we still noticed an induction of c-Cbl binding 
for LynA and LynB upon SFK activation, the effect was minimal and seemed to be 
negated in the LynAY32A mutant. Thus, multiple mechanisms ensure c-Cbl’s interaction 






Figure 3.10. SFK activity is required for rapid degradation of LynA. (A) Immunoblots 
showing expression of transfected wild-type (wt), substrate-binding-impaired (T410K), or 
activation-loop-mutated (Y397F) His6V5-tagged LynA protein coexpressed in JCaM1.6 
cells with memCskAS and c-Cbl and treated with 3-IB-PP1. Interdomain-B-
phosphorylated Zap-70pY319 (pZap-70), an SFK target and prerequisite for Zap-70 
activation, reflects the catalytic activity of LynA; β-Actin is shown as a loading control. 
(B) Overexpression of LynA variants in Jurkat cells. pZap-70 reflects 3-IB-PP1-induced 
Lck activation. (C) Quantification of V5-tagged LynA variants wt (black dotted), T410K 
(gray), and Y397F (orange) in Jurkat cells during 3-IB-PP1 treatment, corrected for total 
protein content (TPS) and reported relative to the steady-state level for each variant of 
LynA. SEM, n=3. Sig. from ANOVA2-Tukey: [T410K vs. wt, gray asterisks], [Y397F vs. 





Figure 3.11. Catalytically dead LynAK275R is not targeted for rapid degradation. (A) 
Immunoblots showing ectopic expression of wild-type (wt, black dotted) and active-site-
mutated (K275R, cyan) His6V5-tagged LynA protein coexpressed in JCaM1.6 cells with 
memCskAS and c-Cbl and treated with 3-IB-PP1. pZap-70 shows the impaired function of 
LynAK275R; β-Actin is shown as a loading control. (B) Quantification of V5-tagged LynA 
protein corrected for total protein content (TPS), reported relative to the steady-state 
level for each LynA variant. SEM, n = 3. Sig. from ANOVA2 with Sidak’s multiple 







Figure 3.12. Mutating Y32 minimally disrupts c-Cbl binding to LynA. (A) 
Representative immunoblot of c-Cbl co-immunoprecipitation by V5-pulldown in Jurkat 
cells transfected with V5-tagged LynA, LynAY32A and LynB. (B) Representative 
immunoblot of c-Cbl co-immunoprecipitation by V5-pulldown in Jurkat cells transfected 
with V5-tagged LynA, LynAY32A and LynB with W100A/T410K/Y397F mutations to 
abolish SH3 binding (W100A), substrate binding (T410K) and activation-loop 
phosphorylation (Y397F). LynA Y32A (no V5 tag) was co-transfected to provide kinase 
activity necessary for c-Cbl activation. (C) Quantification of the amount of c-Cbl co-
immunoprecipitated from Jurkat cells via V5-immunoprecipitation, relative to the amound 





Observing that neither the Jurkat-cell SFKs (Lck/Fyn) nor the myeloid-cell SFK targets 
(Syk and FAK/Pyk2) participate in LynA degradation, we turned our focus to the major 
SFKs in macrophages. We showed above that wild-type LynA is degraded in 3-IB-PP1-
treated Jurkat cells cotransfected with c-Cbl and memCskAS, suggesting that it can 
provide the sole initiating signal to trigger its own degradation, in (i) its ability to induce 
the phosphorylation of LynA Y32 and (ii) its ability to phosphorylate and activate c-Cbl. 
To determine whether this effect could be mediated by LynA and the other macrophage-
expressed SFKs in trans, we performed experiments in which LynAT410K (not degraded 
on its own during 3-IB-PP1 treatment) was coexpressed with kinase-active SFKs in Lck-
deficient JCaM1.6 cells. LynAT410K degradation thus reveals the ability of other SFKs to 
induce both LynA Y32 phosphorylation in trans and c-Cbl activation (Figure 3.13). The 
composition of these transfected samples was assessed by immunoblotting for His6V5-
tagged LynAT410K (for quantification in experimental samples) and wild-type His6V5-
tagged LynA (as a positive control). Wild-type LynA and LynAY32A were used for 
cotransfection as untagged constructs, so they could be resolved on LynA immunoblots 
(Figure 3.13A). Expressed SFKs were visualized using antibodies specific for inactive 
and active SFKs, the V5 epitope tag, and/or individual SFKs (Figure 3.13A). 
Cotransfected SFKs were classified by expression level, by ability to induce 
phosphorylation of the LynAT410K activation loop (pLynAact), of Zap-70 (at an activating 
SFK substrate site in interdomain B [17, 207]), and of c-Cbl at Y731 (an SFK- but not 






Figure 3.13. LynA, LynB, and Hck56kDa can induce rapid degradation of 
cotransfected LynA in trans. (A) Representative immunoblots showing levels of non-
intrinsically degradable His6V5-tagged LynAT410K (#) cotransfected with empty vector or 
active SFK (co) in memCskAS- and c-Cbl-expressing JCaM1.6 cells. Cotransfected SFKs 
include untagged LynA, untagged LynAY32A, His6V5-tagged LynB, the long and short 
isoforms of Hck (Hck59+56), the long isoform of Hck (Hck59), FynT (Fyn), FynB, and Fgr. 
Endogenous FynT was also present. His6V5-tagged LynAT410K# (or wild-type LynA# in the 
positive control condition) was quantified from a total LynA blot (top panel). Colors 
correspond to later figure panels. Coexpressed SFK was visualized via total SFK and 
pSFKinact (inhibitory-tail phosphorylated SFK, corresponding to SrcpY530) blots as 
indicated. pSFKact (activation-loop phosphorylated, corresponding to SrcpY416), pZap-70, 
and p-c-Cbl blots are used to show 3-IB-PP1-induced activity of the cotransfected SFK. 
Erk1/2 is shown as a loading control. When cotransfected with LynAT410K, untagged wild-
type LynA expression was expressed at very low levels, but its presence can be inferred 
based on induction of Zap-70 and c-Cbl phosphorylation with 3-IB-PP1 treatment. 
Endogenous Fyn was also present in the JCaM1.6 cells. (B) Comparison of the 
expression (expr) levels of cotransfected SFKs (SFKco) and their ability to induce 
phosphorylation of the LynAT410K activation loop (pLynAact, the highest band in the 
pSFKact blots), Zap-70pY319 and c-CblpY731 (p-c-Cbl) following 3-IB-PP1 treatment. If 
expression could not be directly compared with the wild-type LynA in the positive-control 
sample (i.e. all constructs except LynA and LynB, which could be compared directly via 
LynA and/or V5 blots), pSFKinact and/or pSFKact blots were used to provide a rough 
estimate of expression, with the caveat that these antibodies may recognize different 
SFK sequences with differing efficiency (marked with asterisks). Despite transfection, 
Fyn expression remained at endogenous levels (endog). The ability of endogenous Lck 
to phosphorylate the activation lop of LynA, interdomain B of Zap-70, and Y731 of c-Cbl 
was assessed in Lck-expressing Jurkat cells transfected with LynAT410K. (C-D) 
Quantification of His6V5-tagged wild-type LynA alone (black dotted, shown as a positive 
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control) or His6V5-tagged LynAT410K alone (gray dotted) or cotransfected with the kinase-
active SFKs. All LynA quantifications (#) are corrected for total protein content (TPS) and 
reported relative to the steady-state level for each transfection condition. SEM, n=5 for 
LynAT410K and LynA alone, SEM, n=4 for all others. Sig. from ANOVA2-Tukey: [LynAT410K 
vs. LynA black asterisks], LynAT410K vs. LynAT410K+LynA, coral asterisks], [LynAT410K vs. 
LynAT410K+LynAY32A, wine asterisks], [LynAT410K vs. LynAT410K+LynB, gold asterisks], 
[LynAT410K vs. LynAT410K+Hck59+56, teal asterisks], [Lyn vs. LynAT410K+Fyn, dark purple 
asterisk]; *** P=0.0007, ** P=0.0017, * P=0.0180-0.0466. Other pairs ns. (C) 
Quantification of His6V5-tagged LynAT410K cotransfected with SFKs that induce greater or 
equal Zap-70 phosphorylation than wild-type LynA alone, a combination of effects from 
protein expression and from the ability of each SFK to phosphorylate Zap-70. These 
include: untagged wild-type LynA (coral), untagged LynAY32A (wine), His6V5-tagged LynB 
(gold dotted), and Hck59+56 (teal). (D) Quantification of His6V5-tagged LynAT410K 
cotransfected with SFKs that induce less pZap-70 than wild-type LynA alone: Hck59 




Cotransfected wild-type LynA, LynAY32A, and LynB were all capable of inducing the 
degradation of LynAT410K in trans. Where depletion of LynAT410K transfected alone was 
undetectable after 5 min of 3-IB-PP1 treatment, cotransfected wild-type LynA, LynAY32A, 
and LynB induced depletion of LynAT410K by 20%, 37%, and 40%, respectively; wild-type 
LynA alone was depleted by 40% at the same time point (Figure 3.13C). Although 
individual cells in a transiently transfected pool express varying levels of each construct, 
we were able to observe trends in bulk expression levels of cotransfected SFKs. As 
reported by the LynA immunoblots for wild-type LynA and LynAY32A (Figure 3.13A) and 
the V5 immunoblots for LynA and LynB, LynAY32A and LynB are more highly expressed 
than wild-type LynA. This is consistent with our previous observations (Figure 3.5). This 
difference in expression could explain the effectiveness of LynAY32A and LynB in inducing 
degradation of LynAT410K; the unique-region substitution in LynAY32A does not noticeably 
block this function or catalytic activity in general, at least compared to similarly 
expressed LynB. Potential differences in activity or signaling specificity, however, would 
be better investigated in a system that does not rely on overexpression.  
 
Expression of Hck from a dual 59 kDa- and 56 kDa-expressing (Hck59+56) plasmid 
induced depletion of LynAT410K by 17% after a 5 min treatment with 3-IB-PP1 (Figure 
3.13C). Based on estimates from pSFK blots, both isoforms of Hck were expressed at 
high levels and pLynAact, pZap-70, and p-c-Cbl were strongly induced (Figure 3.13A-B). 
This activity, however, did not translate into a higher rate of LynAT410K degradation than 
the poorly expressed, cotransfected wild-type LynA (Figure 3.13A-B), suggesting that 
the ability to induce LynA degradation in trans depends on substrate specificity or other 
protein-protein interactions. Hck59 alone was able to phosphorylate the activation loop of 
LynAT410K but unable to phosphorylate Zap-70 or c-Cbl (Figure 3.13A,B,D). This 
suggests that the shorter isoform, Hck56 is the only one capable of inducing Zap-70 
phosphorylation and LynA degradation.  
 
Endogenous Fyn in Jurkat cells is not activated during 3-IB-PP1 treatment (Figure 
3.13A), and we were unable to increase Fyn expression or 3-IB-PP1-induced activation 
by cotransfection. We did, however, detect overexpression and 3-IB-PP1-induced 
activation of a cotransfected brain isoform of Fyn (FynB). Like Hck59, FynB could induce 
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activation-loop phosphorylation of LynAT410K (Figure 3.13B) but did not phosphorylate 
Zap-70 or c-Cbl or induce LynAT410K degradation. 
 
Although neither was able to induce degradation of LynAT410K, Fgr and Lck were 
markedly different from Hck59 and FynB in that, in addition to activation-loop-
phosphorylating LynAT410K, they were also capable of inducing Zap-70 and c-Cbl 
phosphorylation (Figure 3.13B,D).  
 
Overall, these results show that LynA degradation can be induced by SFK activity in 
trans. Activated LynA, LynB, and Hck56 can all mediate LynA degradation to some 
extent, but Lyn appears to do this most efficiently, due either to faster activation kinetics 




3.2.5 Differential expression of c-Cbl tunes LynA protein levels and signaling in 
macrophages and mast cells 
Analysis of data from the Immunological Genome Project (Immgen) shows that mRNA 
expression of Lyn and c-Cbl are differentially regulated across different cell types. Mast 
cells, for instance, express very low levels of c-Cbl mRNA (Figure 3.14) [226, 227], 
which translates into a low level of c-Cbl protein expression [228]. Cbl-b mRNA, in 






Figure 3.14. LynA, c-Cbl, and Cbl-b mRNAs are regulated differentially in myeloid 
cells. Mouse RNAseq data derived from the Immunological Genome Project [ImmGen, 
http://rstats.immgen.org/Skyline/skyline.html, 226, 227]. RNA levels of Lyn, c-Cbl, and 





As in macrophages, Lyn is a key regulator of mast-cell ITAM signaling [229], but the 
effect of disparate Cbl-family expression on LynA in the two cell types remains unknown. 
We generated bone-marrow-derived mast cells from CskAS mice and performed surface 
marker analysis as we had done already for BMDMs [22]. CskAS mast cells were 
homogenous in their expression of traditional mast-cell markers FcεR1α and c-Kit 
(CD117) [176] (Figure 3.15A). We then used immunoblotting to compare the expression 
of Cbl and LynA protein in CskAS mast cells and BMDMs and found that mast cells 
express very little c-Cbl (20% of the level in rested macrophages) and relatively high 
levels of Cbl-b (80% of the level in rested macrophages) (Figure 3.15B-C). Strikingly, 
low c-Cbl expression was accompanied by a complete resistance of LynA to degradation 
in the first 5 min of 3-IB-PP1 treatment (Figure 3.15D). Mast cells also had increased 
steady-state expression of LynA (30% higher than in rested BMDMs) (Figure 3.15E), 
despite low reported mRNA expression (Figure 3.14). These combined effects resulted 
in 3-4x more LynA protein in mast cells than in rested BMDMs and 2x more than in 
primed BMDMs between 3 and 5 min of 3-IB-PP1 treatment. Mast cells also had a 
stronger signaling response to 3-IB-PP1. Although the kinetics of Erk phosphorylation in 
mast cells varied among experiments, induction of pErk1/2 was consistently higher in 
mast cells than in macrophages, including in primed BMDMs (Figure 3.15F). We 
therefore hypothesized that cell-specific expression of c-Cbl tunes steady-state LynA 
protein levels and the persistence of that protein during activation. Since mast cells are 
less dependent on c-Cbl for positive signaling (e.g. as a scaffold in PI3K activation), 
long-lived LynA potentiates a strong response to 3-IB-PP1. Thus mast cells bypass the 
LynA signaling checkpoint by maintaining low levels of c-Cbl and therefore high levels of 
activated LynA. 
 
The relationship between c-Cbl expression, LynA degradation, and sensitivity to SFK-
mediated signaling suggests that the sensitivity of myeloid cells can be tuned by 
changes in c-Cbl expression at the mRNA and/or protein level. To test this effect, we 
transfected mast cells derived from CskAS bone marrow with a small activating (sa)RNA 
duplex [177, 230, 231] designed to increase the expression of c-Cbl. Transfection of this 
saRNA into mast cells increased the expression of c-Cbl protein 2-fold relative to mock-
transfected cells (Figure 3.15G). CskAS mast cells were then treated with 3-IB-PP1 for 
up to 15 min to activate SFKs and assess degradation of LynA and signaling potential as 
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reported by pErk1/2. Even this modest increase in mast-cell c-Cbl expression increased 
LynA degradation in response to 3-IB-PP1 and suppressed downstream phosphorylation 
of Erk1/2 (Figure 3.15I-J). 3-IB-PP1 treatment for 15 min led to a 30% reduction of LynA 
protein in c-Cbl-overexpressing mast cells; LynA degradation at this time point was 
undetectable in control mast cells (Figure 3.15I). Correspondingly, Erk1/2 
phosphorylation was completely suppressed in mast cells treated with c-Cbl saRNA 
relative to control mast cells (Figure 3.15J). Together, these data are consistent with a 
model in which differential expression levels of c-Cbl in myeloid cells regulates the 
activation response of LynA, working together with transcriptional regulation to tune 






Figure 3.15. Differential expression of c-Cbl expression tunes LynA protein levels 
and SFK-mediated downstream signaling in macrophages and mast cells. (A) Flow 
cytometry showing surface expression of the mast-cell markers FcεR1α and c-Kit 
(CD117) in CskAS bone-marrow-derived mast cells (red) compared to a peritoneal B-cell 
control (gray). (B) Immunoblots of CskAS mast cells and BMDMs (mϕ) after resting or 
IFN-γ priming, showing the levels of LynA, c-Cbl, Cbl-b, and pErk1/2 during 3-IB-PP1 
treatment; total Erk1/2 is shown as a loading control. (C-F) Quantification of c-Cbl, Cbl-b, 
LynA, and pErk in mast cells (red), IFN-γ-primed mϕs (dark teal), and rested mϕs (light 
teal). (C) Quantification of steady-state c-Cbl and Cbl-b protein in mast cells and rested 
mϕs, corrected for total protein content (TPS) and reported relative to levels in primed 
mϕs. SEM, n=3. Sig. from one-way ANOVA with Sidak’s multiple comparison test: [mast 
vs. rested mϕs] ** P= 0.0035. Others pairs ns. (D-E) Quantification of LynA in mast cells 
and mϕs during 3-IB-PP1 treatment, corrected for total protein content (TPS) and 
reported relative to the steady-state level of LynA in each cell type (D) or relative to the 
steady-state level of LynA in rested mϕs (E). SEM, n=3 for mast cells and primed mϕs, 
n=4 for rested mϕs. Sig. from ANOVA2-Tukey: [mast vs. rested mϕs, light teal asterisks], 
[mast vs. primed mϕs, dark teal asterisks]; *** P=0.0004-0.0008, ** P=0.0025-0.0088, * 
P=0.0134-0.0466. Other pairs ns. (F) Quantification of pErk1/2 induction during 3-IB-PP1 
treatment, corrected for total Erk1/2 expression and reported relative to the steady-state 
level of pErk1/2 in rested mϕs. SEM, n=3 for mast cells, n=4 for primed mϕs, n=5 for 
rested mϕs. Sig. from ANOVA2-Sidak: [mast vs. rested mϕs, asterisk]; * P=0.0330. Other 
pairs ns. (G) Immunoblots showing steady-state expression of c-Cbl in CskAS mast cells 
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transfected in the presence or absence of Cbl-specific saRNA. Erk1/2 is shown as a 
loading control. (H) Immunoblots showing levels of LynA protein, pSyk, and pErk1/2 
during 3-IB-PP1 treatment of saRNA-transfected or mock-transfected mast cells. (I-J) 
Quantification of LynA and pErk in mast cells with (pink) and without (red) saRNA-
induced upregulation of c-Cbl. SEM, n=3. (I) Quantification of LynA protein during 3-IB-
PP1 treatment, corrected for total protein content (TPS) and reported relative to the 
steady-state level for each transfection condition. Sig. from mixed-effects ANOVA 
analysis: * P= 0.0229. (J) Quantification of pErk1/2 induction during 3-IB-PP1 treatment 
in saRNA-treated and mock-treated mast cells, corrected for total Erk1/2 expression and 
reported relative to the steady-state level for each condition. SEM, n=3 for mast cells. 







Polyubiquitination of kinases and adaptor proteins via the Cbl family can lead to their 
degradation, via the endolysosome or proteasome, and to non-degradation-mediated 
inhibition [84]. These E3 ligases must in turn be tightly regulated to prevent 
hyperresponsive or aberrant immune signaling while maintaining proper pathogen 
clearance [100]. Although highly homologous, c-Cbl and Cbl-b target different subsets of 
signaling proteins for inhibition and/or degradation [85, 232], with c-Cbl polyubiquitinating 
the SFKs, including Lyn [97, 233], and Cbl-b acting on ITAM-coupled receptors, Syk, 
and other kinases [100, 209, 210, 228]. c-Cbl binds via its PTB domain to the SFK 
activation-loop phosphotyrosine [96] and via its PXXP motifs to the SFK SH3 domain 
[205]. It is also a substrate, requiring phosphorylation to become fully activated. These 
binding interfaces promote common c-Cbl interaction with all the SFKs. In this chapter 
we report that c-Cbl targets LynA for rapid and specific degradation, a process that 
occurs with a half-life of a minute in BMDMs. In contrast, other E3 ligases contribute to 
the slower degradation mechanism shared among the other SFKs, including LynB, Fgr, 
Hck59, Hck56, Lck, FynB, and FynT, with the caveat that FynT does not seem to be 
activated in response to 3-IB-PP1. While overexpressed, transfected FynB was able to 
induce LynA Y416 phosphorylation (but not degradation), endogenously expressed Fyn 
(FynT) did not appear to be activated during 3-IB-PP1 treatment. FynB and FynT differ in 
their SH2 domain sequence, suggesting importance for Fyn SH2 in regulating Fyn 
activity. 
 
c-Cbl is targeted to LynA via a noncanonical recognition site present in LynA but not the 
other SFKs. Although LynA and LynB have identical activation kinetics, lipidation sites, 
and activation-loop and SH3-domain sequences, LynA is degraded >10-fold more 
quickly than LynB in macrophages treated with the CskAS inhibitor/SFK activator 3-IB-
PP1 [22]. Exploiting the similarity between LynA and LynB to make a limited set of point 
mutations, we have discovered that, while activation-loop phosphorylation and SH3-
domain interactions mediate slower-phase targeting by c-Cbl and other E3 ligases, rapid 
degradation of LynA is triggered by an interaction peculiar to its unique-domain insert 
region. 
 
We have discovered that Y32 in the unique-region insert of LynA is required for its rapid 
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degradation. This site is rapidly phosphorylated as LynA becomes activated, and this 
event marks LynA for c-Cbl-mediated polyubiquitination. Phosphorylation of LynA Y32 
had been observed in neuroblastoma cell lines upon receptor-tyrosine-kinase activation 
[234]. In epidermoid carcinoma (A431) cells and breast tumor samples LynA Y32 is 
phosphorylated by the epidermal growth factor receptor (EGFR), allowing it to 
phosphorylate MCM-7 and stimulate cell proliferation [214]. We now present evidence of 
LynA Y32 phosphorylation in macrophages, where this potentially positive-regulatory 
function paradoxically induces LynA to trigger its own c-Cbl-mediated polyubiquitination 
and degradation, a process underlying its function as a rheostat controlling the LynA 
checkpoint. 
 
Kinase-impaired variants of LynA are not rapidly degraded, a result confirmed in 
macrophages treated with the SFK inhibitor PP2. Catalytically active LynA and LynB, 
however, can induce degradation of catalytically impaired LynA in trans. Interestingly, 
the shorter isoform of Hck can also induce degradation of LynA, although less efficiently 
than Lyn itself. Degradation of LynA depends on a minimum of two phosphorylation 
events: the phosphorylation of LynA Y32 and activating phosphorylation of c-Cbl [87, 
204]. The ability of individual Src family members to induce LynA degradation 
necessarily rely on the efficiency of these two processes. In cotransfection experiments, 
we found that some SFKs (FynB, Hck59, Fgr, and Lck) were unable to induce 
degradation of kinase dead LynAT410K despite an increase in their own activation-loop 
phosphorylation and their ability to phosphorylate the activation loop of LynAT410K. This 
suggests, perhaps surprisingly [235, 236], that these kinases are not localized away 
from LynA or otherwise lacking in activity. Instead, it is likely that the induction of LynA 
degradation occurs via specific protein-protein interactions and/or substrate recognition 
interfaces. Unlike FynB and Hck59, Fgr and Lck were surprisingly able to phosphorylate 
c-Cbl, despite c-Cbl being reported to be a poor substrate for Lck and Zap-70 [204]. 
Again, this suggests that the substrate preferences of the Src family members are 
regulated. On the other hand, Syk and FynT have both been reported to phosphorylate 
and activate c-Cbl [204], but LynA degradation in 3-IB-PP1-treated BMDMs is unaffected 
by Syk inhibition and Fyn is not activated during 3-IB-PP1 treatment. 
 
Rapid degradation of LynA is easily observed upon bulk SFK activation by 3-IB-PP1 but 
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also affects the steady-state level of LynA protein, likely due to the selective degradation 
of small amounts of basally active [22] LynA over time. Although the unique region of 
LynA lacks a c-Cbl consensus recognition motif [85], pY32 could serve as a docking site 
for the PTB domain of c-Cbl. In this ultrafast feedback process, activation-loop- and Y32-
autophosphorylated LynA could efficiently phosphorylate and activate c-Cbl and facilitate 
its own degradation, potentially then releasing c-Cbl for other positive and negative 
regulatory signaling functions. Earlier work has shown that although the interactome of 
transfected LynAY32F in mammary adenocarcinoma (MDA-MB-231) cells more closely 
resembles that of wild-type LynA than LynB, some LynA interactions are lost [150]. It is 
also possible that, by analogy to a similarly situated but non-homologous 
phosphorylation site in Hck (pY29) [38], phosphorylation of LynA Y32 could be directly 
activating. The unique regions of LynA and LynB make distinct SH3-domain contacts 
[42], and phosphorylation could alter these interactions, leading to increased kinase 
activity. Hyperactivated LynA could then efficiently phosphorylate and activate nearby or 
pre-complexed c-Cbl, triggering its own degradation more aggressively than do the other 
SFKs. 
 
LynA and LynB have been reported to interact with different subsets of proteins in mast 
cells and in triple-negative breast cancer cells, with LynA signaling via ITAM [149], 
cytoskeletal, and proliferative [150] pathways and LynB initiating negative feedback via 
ITIMs and phosphatases [149]. In mammary epithelial cells the ratio of LynA and LynB is 
actively regulated by Epithelial Splicing Regulatory Protein 1 (ESRP1), with LynA-
upregulated tumors having the more invasive phenotype [150]. The positive-regulatory 
roles reported for LynA in mast and tumor cells complements our own observations that 
LynA degradation can block macrophage signaling through the Erk, Akt, and NFAT 
pathways, which cannot be rescued by active LynB [22]. 
 
Aberrant activation driven by ITAM signaling pathways in macrophages is a known driver 
of autoimmune and inflammatory disease, with activated macrophages accumulating in 
chronically inflamed tissues in the absence of an active infection [237]. Regulation of 
LynA protein expression and deactivation kinetics by c-Cbl could, via the LynA 
checkpoint, prevent the initiation of pathological signaling. The threshold for macrophage 
activation is modulated by changes to their local environment. For example, IFN- and 
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LPS polarize macrophages for a pro-inflammatory response, whereas IL-4 and IL-13 
polarize macrophages for tissue repair (i.e. collagen deposition) and inflammatory 
resolution [4, 238]. We have reported that IFN- decreases the macrophage signaling 
threshold in part by increasing the expression of LynA [22]. Dynamic changes in SFK 
and c-Cbl levels could modulate the macrophage activation threshold, ensuring that 
macrophages respond appropriately during times of infection (low threshold) and limiting 
aberrant activation in response to cellular debris and small-scale antibody complexes 
during inflammatory resolution (high threshold). 
 
Like macrophages, mast cells reside in nearly every bodily tissue and perform 
environment-specific functions in addition to sensing non-self [238, 239]. While 
macrophages have distinct anti-inflammatory roles as professional phagocytes in the 
silent clearance of apoptotic cells and agents of wound healing, mast cells are 
constitutively primed for ITAM-induced triggering, releasing preformed granules that 
contain inflammatory cytokines, chemokines, prostaglandins, and proteases. Pursuant to 
these differing functions, macrophages continuously gauge ITAM ligand valency (i.e. 
particle size) and have a relatively high basal threshold for inflammatory activation [22, 
62], while mast cells can be triggered by small-scale receptor clustering induced by low-
valency or even monovalent FcεR-IgE-allergen complexes [196, 197]. One striking 
difference between the macrophage and mast-cell ITAM regulatory machinery is that 
mast cells express almost no c-Cbl. In spite of low reported mRNA levels (Immgen, [226, 
227]), mast cells constitutively express a high level of LynA protein, likely due to 
impaired steady-state degradation of basally active LynA. Furthermore, LynA is not 
degraded upon activation and 3-IB-PP1 triggers a stronger Erk phosphorylation 
response in the absence of ITAM-receptor ligation in mast cells than in rested 
macrophages. 
 
Overall, we describe a model in which regulation of LynA and c-Cbl levels helps to 
determine an immune cell’s potential for inflammatory ITAM signaling. Regulated 
degradation tunes down the LynA rheostat, blocking cell signaling via the LynA 
checkpoint at low cellular doses of LynA and overriding the LynA checkpoint at higher 
doses. In macrophages, this occurs on a continuum where LynA dose is highest in cells 
rendered more reactive by IFN-γ priming (polarization). Mast cells express almost no c-
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Cbl and maintain high levels of LynA at steady state and over time, consistent with 
permissive signaling in the absence of a large-scale ITAM receptor clustering event 
nucleated by multivalent receptor ligation. Appropriate regulation of immune receptor 
thresholds is critical for maintaining the function of innate immune cells; threshold 
dysregulation can lead to chronic feedback loops that drive inflammatory signaling in 
autoimmune disease and conversely tumor-supporting immunosuppressive signaling 
[237]. Elucidating the mechanisms by which the LynA checkpoint is regulated may allow 
us to tune immune-cell sensitivity and reprogram pathological cells 
 
3.4 Footnotes 
Portions of this text have been previously published and adapted here:  
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Habib N, Drake JM, Schwertfeger KL, Freedman TS. Unique-region phosphorylation 
targets LynA for rapid degradation, tuning its expression and signaling in myeloid cells. 
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CHAPTER 4:  CRISPR-based constraint of lyn splicing reveals a 
unique function of LynB in suppressing autoimmunity 
 
4.1  Introduction 
Autoimmune diseases comprise a spectrum of disorders in which the immune system 
mounts an improperly regulated immune response against self-antigens, or regulatory 
mechanisms fail to limit excessive inflammation [240-242]. The development and 
progression of autoimmunity can have many causes and drivers, including dysregulated 
immune-cell signaling [80, 111, 243]. Understanding how immunoreceptor signaling is 
regulated is imperative to develop therapies that limit immune activation but preserve the 
immune system’s ability to eliminate pathogens. 
 
The tyrosine kinase Lyn has been implicated in the development or progression of 
several autoimmune diseases, especially in human systemic lupus erythematosus 
(SLE). Polymorphisms in the LYN gene are risk factors for SLE [139, 244] and patients 
with lupus often have deficiencies in Lyn expression, signaling or trafficking [136, 138]. 
In both human and mice, Lyn is expressed in B cells and myeloid cells, as well as non-
hematopoietic cells such as neurons and epithelial cells, and transmits signals 
downstream of a number of receptors, including immunoreceptor tyrosine-based 
activation motif (ITAM)-coupled receptors such as the B-cell receptor (BCR) [12, 104, 
133] and Fc receptors (FcRs) [141]. Lyn also signals downstream of non-ITAM-coupled 
receptors such as integrins [245], and Toll-like receptors (TLRs) [117, 119]. Importantly, 
Lyn also associates with and signals downstream of immunoreceptor tyrosine inhibitory 
motif (ITIM) receptors such as CD22 [133, 246, 247], leading to the activation of 
phosphatases such as SHP-1 and SHIP-1, that act as important brakes on inflammatory 
signaling. Lyn is unique amongst the Src-family kinases in its ability to activate pathways 
that both promote and inhibit cellular activation [12, 151, 248]. Understanding how Lyn is 
able to mediate both positive and negative signaling in immune cells is critical for 
understanding the development and progression of autoimmune diseases and 
developing treatments that selectively suppress immune function. 
 
In mouse models, global Lyn knock-out mice develop an age-onset autoimmune disease 
that partially resembles human SLE, including the production of anti-nuclear antibodies 
(ANAs), and the development of splenomegaly and glomerulonephritis [249]. Similar 
 
84 
phenotypes are observed in B cell-selective [118] and dendritic-cell-selective [114, 117] 
Lyn knockout (LynKO) mice, underscoring that Lyn deficiency in multiple Lyn-expressing 
cell types contributes to the development of autoimmunity. The development of 
autoimmune disease in LynKO mice can be abrogated by concomitantly knocking out 
downstream signaling proteins such as CARD9 [119], modulators of actin dynamics 
such as Ezrin [250], and TLR signaling components, such as MyD88 [117, 118, 183] and 
IRF5 [120], revealing that a wide array of activated signaling pathways contributes to 
disease development in the absence of Lyn. 
 
MyD88 is an adaptor protein that links multiple TLRs, including TLR4 and TLR9, to 
downstream signaling and cellular activation [251]. TLR4 normally senses 
lipopolysaccharides generated by gram-negative bacteria and TLR9 normally responds 
to single-stranded DNA (ssDNA) with unmethylated CpG motifs often found in microbial 
DNA. Both TLR4 signaling and overexpression have been implicated in human SLE and 
mouse models of lupus [126, 128, 130, 131, 252]. Lyn has been shown to negatively 
regulate TLR4 and TLR9 signaling in dendritic cells [117, 119, 120]. However, Lyn has 
also been shown to positively regulate TLR4 signaling in mast cells and macrophages 
[124, 125]. A detailed, molecular understanding of how Lyn interacts with and 
differentially regulates TLR4 and TLR9 signaling in multiple cell types remains 
incomplete. 
 
mRNA from the lyn gene can be alternatively spliced to produce two proteins, LynA (the 
longer isoform) and LynB. LynA contains a 21-amino-acid-insert near its N-terminus, in 
the unique region of the SFKs. Previous research suggests that LynA and LynB can 
interact with different proteins and modify different signaling pathways. Lentiviral 
expression of LynA or LynB in LynKO mast cells revealed that LynA has a greater 
propensity to activate downstream signaling after FcεR ligation whereas LynB was better 
able to activate inhibitory phosphatases [149]. Similarly, breast cancer cells had a more 
invasive phenotype when reconstituted with LynA [150], suggesting that LynA associates 
more with activating signaling pathways than LynB. Furthermore, analysis of proteins 
that immunoprecipitate with LynA showed an enhancement of proteins related to 
cytoskeletal rearrangement, further suggesting differential interactomes of LynA and 
LynB. Additional data suggests that the 21-amino-acid-insert of LynA may make 
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important intramolecular contacts with other regulatory domains, including the Src-
homology 3 (SH3) domain, that may further differentiate the regulatory mechanisms that 
control LynA and LynB activity [42]. 
 
Our previous research has uncovered unique regulatory mechanisms and functions of 
LynA and LynB that suggest unique roles in regulating immune function. Using CskAS 
transgenic mice, we identified a unique role for LynA in promoting macrophage pro-
inflammatory signaling [22]. CskAS mice express a transgenic Csk mutant that can be 
specifically inhibited by the small molecule 3-IB-PP1 [70]. Treating CskAS macrophages 
with 3-IB-PP1 induces global SFK activation and rapid poly-ubiquitin-mediated 
degradation of LynA, which occurs on a much faster time scale than LynB and other 
SFKs expressed in macrophages [22]. The rapid degradation of LynA prevents 
activation of downstream proteins, such as MAPK/Erk and Akt. However, treating 
(priming) macrophages with inflammatory cytokines, such as IFN-γ, upregulates the 
protein levels of LynA and LynB and restores downstream signaling upon SFK 
activation. Elucidating how LynA and LynB may contribute differentially to macrophage 
activation and priming-dependent signaling has been complicated by a lack of genetic 
models that enable LynA and LynB to be studied independently. 
 
To investigate the functions of LynA and LynB, we used CRISPR-Cas9 to create novel 
knockout models to study LynA and LynB independently. We show that LynBKO mice 
develop splenomegaly, produce anti-nuclear antibodies and develop glomerulonephritis, 
suggesting that LynB, in particular, has a negative regulatory role and prevents the 
development of autoimmune disease in mice. Furthermore, circulating immune cells in 
LynBKO mice also have increased expression of TLR4, but not other TLRs. Finally, we 
show the LynB-deficiency increases the responsiveness of certain immune cells to TLR4 





4.2  Results 
4.2.1 Generation of LynAKO and LynBKO mice 
LynA is produced by splicing exon 2 and 3 of the lyn gene, whereas LynB is spliced from 
a cryptic splice site in exon 2 (Figure 4.1A). To generate LynAKO mice we injected 
mouse embryos with preformed ribonucleoprotein complexes [182, 253] containing Cas9 
and two guide (g)RNAs to induce two cuts in the region of the lyn exon 2 that encodes 
the unique insert of LynA, 3’ of the cryptic LynB splice site (Figure 4.1B). Repair of the 
resulting deletion and double-strand break by non-homologous end joining (NHEJ) 
resulted in a deletion and frameshift, facilitating screening and ensuring selective loss of 
LynA expression. After implantation and birth, pups were screened via PCR and 
restriction digest; candidates yielding truncated PCR products (due to the exon-2 
deletion) and maintaining a cut site for SnaBI near the LynB splice junction were found 
to be single-allele carriers of the LynA deletion and bred to homozygosity. Three founder 
candidates were verified by PCR sequencing. Of these, one mutation was sufficiently 
close to the exon-2 splice junction to disrupt LynB protein expression, and one initially 
bred slowly. Therefore, we proceeded with mice derived from a single founder, 
“LynAKO(CRISPR)”, in which the LynA sequence is scrambled after amino-acid residue 
30, four residues into the LynA unique-region insert, followed by a premature stop codon 






Figure 4.1. Generation of LynAKO and LynBKO mice  
(A) A cryptic splice junction in exon 2 allows for alternative splicing of the lyn gene, 
producing LynA and LynB (B) LynAKO mice were created using dual gRNAs and NHEJ, 
resulting in a deletion within the LynA insert sequence and a premature stop codon after 
the cryptic LynB splice acceptor site in exon 2. (C) LynBKO mice were created using one 
gRNA and a donor oligonucleotide sequence encoding two point mutations: one to 
inactivate the LynB splice acceptor site and another (silent) mutation to ablate a SnaB1 
restriction enzyme cleavage site for PCR-based screening. In the LynBKO mice, LynA(*) is 





Figure 4.2. Genomic and protein sequence generated in LynAKO mice. Genomic and 
proteins sequences of exon 2 (yellow) and exon 3 (green) of the mouse lyn gene, 
illustrating the cryptic LynB splice site (boxed) and LynA unique region (cyan), and 
illustrating the truncated protein products from CRISPR gene editing in the LynAKO mice. 
WT mouse lyn 
 
5’ region of exon 2 (shared by LynA & LynB) 
 splice site (GT) & restriction site (TACGTA) in exon 22 
3’ region of exon 2 (LynA only) 
exon 3 (shared) 
exon 4 
intron 











LynA sequence in LynAKO 
 
DNA notation (connecting mRNA splice junctions) 
 
WT  ATGGGATGTATTAAATCAAAAAGGAAAGACAATCTCAATGACGATGAAGTAGATTCGAAGACTCAACCAGTACGTAATACTGACCGAACTATTTA 
MUT ATGGGATGTATTAAATCAAAAAGGAAAGACAATCTCAATGACGATGAAGTAGATTCGAAGACTCAACCAGTACGTAATACTGACCGAACAGAGAC 
    *********************************************************************************************** 
 
WT  TGTGAGAGATCCAACGTCCAATAAACAGCAAAGGCCAGTTCCTGAATTTCATCTTTTACCAGGACAGAGATTTCAAACAAAAGATCCAGAGGAAC 
MUT -------------------------------------GTTCCTGAATTTCATCTTTTACCAGGACAGAGATTTCAAACAAAAGATCCAGAGGAAC 
                                         ********************************************************** 
 
WT  AAGGTGACATTGTGGTGGCCTTATACCCTTATGATGGCATCCACCCAGATGACTTGTCCTTCAAGAAAGGAGAAAAGATGAAAGTTCTAGAAGA… 
MUT AAGGTGACATTGTGGTGGCCTTATACCCTTATGATGGCATCCACCCAGATGACTTGTCCTTCAAGAAAGGAGAAAAGATGAAAGTTCTAGAAGA… 




WT  MGCIKSKRKDNLNDDEVDSKTQPVRNTDRTIYVRDPTSNKQQRPVPEFHLLPGQRFQTKDPEEQGDIVVALYPYDGIHPDDLSFKKGEKMKVLE… 
MUT MGCIKSKRKDNLNDDEVDSKTQPVRNTDRTETFLNFIFYQDRDFKQKIQRNKVTLWWPYTLMMASTQMTCPSRKEKR-              94 
    ******************************                                             77   
    1                                                                                         
 
LynB sequence in LynAKO 
 
DNA notation (connecting mRNA splice junctions) 
 
WT  ATGGGATGTATTAAATCAAAAAGGAAAGACAATCTCAATGACGATGAAGTAGATTCGAAGACTCAACCAGTTCCTGAATTTCATCTTTTACCAGG 
MUT ATGGGATGTATTAAATCAAAAAGGAAAGACAATCTCAATGACGATGAAGTAGATTCGAAGACTCAACCAGTTCCTGAATTTCATCTTTTACCAGG 
    *********************************************************************************************** 
 
WT  ACAGAGATTTCAAACAAAAGATCCAGAGGAACAAGGTGACATTGTGGTGGCCTTATACCCTTATGATGGCATCCACCCAGATGACTTGTCCTTCA 
MUT ACAGAGATTTCAAACAAAAGATCCAGAGGAACAAGGTGACATTGTGGTGGCCTTATACCCTTATGATGGCATCCACCCAGATGACTTGTCCTTCA 
    *********************************************************************************************** 
 
WT  AGAAAGGAGAAAAGATGAAAGTTCTAGAAGA… 
MUT AGAAAGGAGAAAAGATGAAAGTTCTAGAAGA…                 
    ******************************* 
Translation 
 
WT  MGCIKSKRKDNLNDDEVDSKTQPVPEFHLLPGQRFQTKDPEEQGDIVVALYPYDGIHPDDLSFKKGEKMKVLE… 
MUT MGCIKSKRKDNLNDDEVDSKTQPVPEFHLLPGQRFQTKDPEEQGDIVVALYPYDGIHPDDLSFKKGEKMKVLE… 
    ************************************************************************* 





Figure 4.3. Genomic and protein sequence generated in LynBKO mice. Genomic and 
proteins sequences of exon 2 (yellow) and exon 3 (green) of the mouse lyn gene, 
illustrating the cryptic LynB splice site (boxed) and LynA unique region (cyan), and 




WT mouse lyn 
 
5’ region of exon 2 (shared by LynA & LynB) 
 splice site (GT) & restriction site (TACGTA) in exon 21  
3’ region of exon 2 (LynA only) 
exon 3 (shared) 
exon 4 
intron 











(no LynB due to mutation of splice site) 
 
LynA sequence in LynBKO 
 
DNA notation (connecting mRNA splice junctions) 
 
WT  ATGGGATGTATTAAATCAAAAAGGAAAGACAATCTCAATGACGATGAAGTAGATTCGAAGACTCAACCAGTACGTAATACTGACCGAACTATTTA 
MUT ATGGGATGTATTAAATCAAAAAGGAAAGACAATCTCAATGACGATGAAGTAGATTCGAAGACTCAACCACTGCGTAATACTGACCGAACTATTTA 
    ********************************************************************* * *********************** 
    1                                                                                          95 
 
WT  TGTGAGAGATCCAACGTCCAATAAACAGCAAAGGCCAGTTCCTGAATTTCATCTTTTACCAGGACAGAGATTTCAAACAAAAGATCCAGAGGAAC 
MUT TGTGAGAGATCCAACGTCCAATAAACAGCAAAGGCCAGTTCCTGAATTTCATCTTTTACCAGGACAGAGATTTCAAACAAAAGATCCAGAGGAAC 
    *********************************************************************************************** 
    96                                                                                          190 
 
WT  AAGGTGACATTGTGGTGGCCTTATACCCTTATGATGGCATCCACCCAGATGACTTGTCCTTCAAGAAAGGAGAAAAGATGAAAGTTCTAGAAGA… 
MUT AAGGTGACATTGTGGTGGCCTTATACCCTTATGATGGCATCCACCCAGATGACTTGTCCTTCAAGAAAGGAGAAAAGATGAAAGTTCTAGAAGA… 
    ********************************************************************************************** 




WT  MGCIKSKRKDNLNDDEVDSKTQPVRNTDRTIYVRDPTSNKQQRPVPEFHLLPGQRFQTKDPEEQGDIVVALYPYDGIHPDDLSFKKGEKMKVLE… 
MUT MGCIKSKRKDNLNDDEVDSKTQPLRNTDRTIYVRDPTSNKQQRPVPEFHLLPGQRFQTKDPEEQGDIVVALYPYDGIHPDDLSFKKGEKMKVLE… 
    ***********************:********************************************************************** 




To generate LynBKO mice we used a single gRNA to induce a Cas9 cut near the cryptic 
LynB splice site in lyn exon 2. Homology-directed repair (HDR) was then templated from 
a donor oligonucleotide (Figure 4.1C) with two single-nucleotide substitutions, one to 
ablate the splice site and one silent mutation to ablate a SnaBI restriction site for 
restriction-based screening. Candidates resistant to SnaBI were found by PCR 
sequencing to be heterozygous for the splice-site mutation and were bred to 
homozygosity. We proceeded with the best breeder of two candidates. This strain 
bearing two alleles of “LynBKO(CRISPR)” results in expression of LynA with a 
conservative valine (V)-to-leucine (L) substitution at position 24 in the unique region; the 
SnaBI restriction-site mutation is silent (Figure 4.3). 
 
To test whether V24 substitution alters the function of LynA, we compared the signaling 
responses of LynA, LynAV24L and LynAV24A, transiently transfected into JCaM1.6 T cells, 
which lack the endogenous SFK Lck. In this model, activated LynA is required to initiate 
downstream signaling [27]. To induce LynA activation, we co-transfected JCaM1.6 cells 
with a membrane-localized variant of Csk (memCskAS) that is sensitized to inhibition via 
the small molecule 3-IB-PP1 [27, 70]. Addition of 3-IB-PP1 to memCskAS-transfected 
cells induces activation of the SFKs (including transfected LynA [27]) without the 
requirement for TCR crosslinking [70]. Downstream signaling, as assessed by Erk 
phosphorylation, was unaffected in LynA, LynAV24A and LynAV24L-expressing cells, but 
blocked in cells expressing a kinase-dead variant, LynAT410K/Y397F, suggesting that LynA 
kinase activity and interactions with Syk and other substrates are not disrupted (Figure 
4.4A,B). To further investigate whether LynAV24L substitution alters LynA regulation, we 
bred LynBKO mice to CskAS-transgenic mice to generate CskASLynBKO mice. We have 
previously shown that LynA is rapidly degraded in CskAS bone-marrow derived 
macrophages (BMDMs) following treatment with 3-IB-PP1. We saw no difference in 
LynA degradation between CskAS and CskASLynBKO (Figure 4.4C,D), suggesting the 
V24L substation does not affect LynA regulation. To further control for any effect of this 
unique-region substitution on LynA function, we performed initial studies with mice 
produced from an F1 cross of homozygous LynAKO and LynBKO parents (F1: “ABhemi”), 
which express LynAV24L and LynB from one allele each (Figure 4.5A). For simplicity, we 





Figure 4.4. V24L substitution does not affect LynA degradation or signaling. (A) 
Representative immunoblot of JCam1.6 cells transfected with LynA, LynAV24A, LynAV24L 
and LynAT410K/Y397 mutants along with membrane-anchored CskAS (memCskAS) and 
treated with CskAS inhibitor 3-IB-PP1. (B) Quantification of pErk activation in (A) 
normalized to the amount of LynA protein at t=0. (C) Representative immunoblot of 
CskAS and CskASLynBKO BMDMs treated with 3-IB-PP1. (D) Quantification of LynA 





We next probed Lyn protein expression in BMDMs from LynAKO and LynBKO mice and 
found the expected pattern of deficiency (LynA absent in the homozygous LynAKO 
(LynAKOLynB+/+) and LynB absent in the homozygous LynBKO (LynBKOLynA+/+) (Figure 
4.5B). To our surprise, however, the protein level of the remaining Lyn isoform (LynB in 
the homozygous LynAKO and LynA in the homozygous LynBKO) was ~2.5x elevated 
relative to WT (Figure 4.5B-D), suggesting feedback compensation. Compensating for 
the loss of a SFK by upregulating other SFKs has been previously described [254]. 
However, we detected no differences in other SFK expression in BMDMs derived by 
LynAKO and LynBKO mice (Figure 4.5B). We created hemizygous LynAKOLynB+/- and 
LynBKOLynA+/- mice by breeding the LynAKO and LynBKO homozygous mice to LynKO 
mice, which lack both LynA and LynB due to a homozygous Neomycin insertion 
(LynKO(NEO)) (Figure 4.5A) Mice that express only one allele of LynA or LynB 
(genotype LynAKO(CRISPR)/LynKO(NEO), protein-expression phenotype LynAKOLynB+/- 
or genotype LynBKO(CRISPR)/LynKO(NEO), protein-expression phenotype LynBKOLynA+/-
, express physiological levels of LynA and LynB, respectively (Figure 4.5B-D).  
 
We have previously shown that priming macrophages for 12-16 hours with interferon 
(IFN)-γ induces transcriptional upregulation of Lyn. This response to inflammatory 
priming was preserved in all LynAKO and LynBKO BMDMs (Figure 4.5E-G). 
 
We have previously shown that the ubiquitin ligase c-Cbl regulates the protein level of 
LynA in macrophages and that c-Cbl-expression controls the magnitude of LynA 
signaling. We wondered whether LynA deletion conversely feeds back to alter 
expression of c-Cbl. We probed BMDMs from knockout mice for expression c-Cbl, and 
the closely related E3 ligase Cbl-b, expression. We found that BMDMs from LynBKO mice 
have increased levels of c-Cbl, while Cbl-b be levels were unaffected in LynAKO and 
LynBKO mice (Figure 4.6). This suggests that c-Cbl-expression levels are regulated in 





We performed  future experiments using hemizygous mice, as opposed to the 
LynAKOLynB+/+ an LynBKOLynA+/+ homozygous mice. For simplicity, the hemizygous mice 






Figure 4.5. SFK expression and regulation is normal in LynAKO and LynBKO mice. 
(A) Breeding scheme used to generate LynAKO and LynBKO mice and ABhemi mice. (B) 
Immunoblot showing Lyn, Fyn, Fgr and Hck expression in BMDMs from WT, LynAKO, 
LynBKO and ABhemi and LynKO mice. Erk1/2 is shown as a loading control. (C) 
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Quantification of LynA and (D) LynB protein levels in BMDMs derived from the breeding 
scheme in (A). Stars represent hemizygous mice for the expressed isoform of Lyn, 
which will be used for all future experiment. Results from n=2 immunoblots. (E) 
Representative immunoblot of untreated and IFN-γ-treated BMDMs from CRISPR 
knockout mice. (F) Quantification of LynA protein and (G) LynB protein in IFN-γ-treated 






Figure 4.6. LynA and c-Cbl are co-regulated. (A) Immunoblot of LynA, LynB, c-Cbl 
and Cbl-b in BMDMs from WT, LynAKO, LynBKO and ABhemi and LynKO mice. Total protein 
is shown as a loading control. (B) Quantification of c-Cbl and (D) Cbl-b protein levels in 





4.2.2 LynB deletion predisposes mice to develop splenomegaly  
Lyn has a prominent role in suppressing hematopoiesis and cell proliferation [151]. 
LynKO mice develop a myeloproliferative syndrome characterized by an increase in 
spleen mass (splenomegaly) driven by increased numbers of neutrophils, eosinophils 
and monocytes. This phenotype is myeloid-cell-intrinsic, as depletion of B and T cells in 
LynKO mice does not affect the progression of splenomegaly [151, 152]. The 
development of splenomegaly in LynKO mice is age-dependent and generally occurs 
between 6-8 months of age [117, 118, 151]. Despite the intriguing evidence that LynA 
and LynB may differentially regulate cancer-cell migration [150] and FcεR-ITAM-pathway 
signaling [149], the contributions of LynA and LynB in driving splenomegaly is unknown. 
 
We saw no differences in spleen mass at 3 months in any of the genotypes (Figure 
4.7A). Although we detected a small decrease in body mass of 3-month-old male and 
female LynBKO mice (Figure 4.7B), there was no corresponding increase in the size of 
the spleens in comparison to body mass (Figure 4.7C). We next compared the spleen 
mass of 8-month-old knockout mice. We discovered that spleen mass was 2.6-fold and 
2.1-fold significantly increased in LynKO and LynBKO mice respectively (Figure 4.7C, D). 
Furthermore, the body mass of LynKO and LynBKO mice was significantly decreased 
compared to WT mice (17% and 18% lower, respectively) (Figure 4.7E). 
Correspondingly, the splenic mass in relation to body mass (Figure 4.7F) was 
significantly increased in LynKO (3.1-fold) and LynBKO (2.6-fold). ABhemi mice (LynA-/-
LynB+/+ x LynA+/+LynB-/-) had similar spleen and body mass to WT mice, demonstrating 
that the CRISPR-induced mutations preserve normal LynA and LynB function. When we 
characterized the incidence of mild splenomegaly (0.45%-0.75% body mass) and severe 
splenomegaly (>0.75% of body mass) we found that both LynBKO and LynKO mice had a 
significant increase in the rate of splenomegaly, suggesting that LynB negatively 






Figure 4.7. Loss of LynB predisposes aged mice to splenomegaly. (A) Total spleen 
mass, (B) Total body mass, and (C) Spleen mass as a percentage of body mass of 3-
month-old mice. (A) Representative spleens based on mass quantification of 8-month-
old mice. Scale bar = 1 cm. (D) Total spleen mass, (E) Total body mass, and (F) Spleen 
mass as a percentage of body mass of 8-month-old mice Squares represent male mice, 
circles represent female mice. The significance (Sig.) from one-way ANOVA with 
Tukey’s multiple comparison test (-Tukey) are as follows: **** P<0.0001, *** P<0.0002, ** 
P<0.0021,* P<0.0332. Error bars represent mean with 95% confidence interval. (G) 
Frequency of spleens with no, mild and severe cases of splenomegaly in 8-month-old 
WT, LynAKO, LynBKO, LynKO, and ABhemi mice. Significance for raw contingency data was 
assessed using two-sided Fisher's exact test (GraphPad Prism) from binarized data 
reflecting animal numbers with no or mild vs. severe splenomegaly without correction for 
multiple comparisons. With Bonferroni Correction, significance is preserved for pairwise 
comparisons with the exception of [LynBKO vs. F1] and [LynKO vs. F1]  
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4.2.3 LynBKO mice have selective myeloid expansion and B cell activation  
We proceeded to further characterize the spleens of 8-month-old knockout mice. Lyn is 
known to regulate the development of monocytes and previous research has shown that 
LynKO mice have increased numbers of total monocytes, and a skewing of monocytes 
towards Ly6C— patrolling monocytes [117, 151, 255]. Accordingly, we found that 8-
month-old LynKO mice had increased numbers of spleen monocytes (Figure 4.8A), both 
classical and patrolling. LynBKO mice also had an increase in patrolling monocytes 
compared to WT mice, although less than total LynKO mice. Interestingly, we discovered 
that LynBKO mice had a selective expansion of mature, CD64+ CD11b— MerTK+ 
macrophages (Figure 4.8B). This population has not previously been studied in LynKO 
mice, and together these results suggest that LynB normally exerts a negative role in the 
development of monocytes and macrophages. 
 
Lyn has been shown to negatively regulate dendritic cell development in cultured bone-
marrow cells treated with GM-CSF, and via selective deletion of Lyn using Cre-
recombinase under the control of the CD11c promoter [117, 256]. We found no 
differences in the numbers of spleen dendritic cells in WT and global LynKO mice, 
however we did discover that both LynAKO and LynBKO had increased numbers of 
conventional DC (cDC) but that this increase was heavily skewed towards cDC2s, 
especially for LynBKO mice (Figure 4.8C). cDC2 are important regulators of CD4 T cell 
activation [257, 258]. The expansion of cDC2s in LynBKO mice fits with an increase in the 
numbers of CD4+ T cells in LynBKO and LynAKO mice that we also observed (Figure 
4.10A-D). We further discovered the LynBKO mice had increased numbers of 
plasmacytoid DC3 (pDC) (Figure 4.8D). pDC are potent cytokine secretors and have 
been implicated in autoimmune disease development [259] and Lyn has also been 
shown to regulate pDC function [123]. 
 
Although LynB deletion resulted in an increase in monocytes, we did not detect any 
increase in the numbers of granulocytes (neutrophils and eosinophils) in the spleens of 
LynBKO mice (Figure 4.8E). Thus, LynB deletion appears to have selective effects on 




Previous research has shown that LynKO mice have a substantial defect in B-cell 
development, leading to a lack of mature splenic B cells. We examined 8-month-old 
spleens by hematoxylin and eosin (H&E) staining to examine cellular distribution and 
organization to investigate whether Lyn expression affects splenic architecture and B-
cell follicle organization. We observed that LynAKO mice had increased numbers and 
larger follicles than WT mice, whereas LynBKO mice had smaller and less organized B 
cell follicles (Figure 4.9A). LynKO mice had very few observable follicles, likely due to the 
defect in B-cell maturation. We further examined B-cell populations in the spleen by flow 
cytometry and found that LynA expression (LynBKO mice) restores the number of mature 
B cells to WT levels, but that expression of LynB (LynAKO) leads to increased numbers of 
B cells compared to WT mice (Figure 4.9B). We further probed B-cell subsets in older 
mice and discovered that both LynAKO and LynBKO had higher total numbers of cells with 
a GL7+ CD38- germinal center (GC) phenotype (Figure 4.9C). The fraction of B220+ B 
cells with GC phenotype was elevated in both LynAKO and LynBKO mice, but higher in 
LynBKO mice (Figure 4.9D). Furthermore, the CD69 and MHCII mean fluorescence index 
(MFI) of B220+ B cells was significantly elevated in both LynBKO and LynKO (Figure 
4.9E,F) and GC B cells had higher CD69 expression in LynB-deficient mice (Figure 
4.9G). These data suggest that loss of LynB induces B cell activation, without a 
corresponding defect in B cell development and maturation, although whether these 
changes are B-cell intrinsic or related to changes to myeloid and dendritic cells remains 
to be investigated. 
 
In summary, loss of either LynA or LynB induces unique changes in spleen immune 
cells. LynBKO mice have increased numbers of mature macrophages, patrolling 
monocytes, conventional Type 2, and plasmacytoid dendritic cells.  LynBKO mice also 
have normal numbers of B cells compared to WT mice, but increased numbers of GC  
and activated B cells. In contrast, LynAKO mice have increased numbers of B cells, and 






Figure 4.8. LynBKO mice have selective myeloid expansion. (A) Total monocytes, 
classical monocytes and patrolling monocytes, (B) Total CD64+ MerTK+ mature 
macrophages, (C) Total conventional dendritic cells (cDC), Type 1 cDC (cDC1) and 
Type 2 cDC (cDC2), (D) total plasmacytoid dendritic cells (pDC) (E) and granulocytes 
per spleen of 8-month-old mice, relative to WT mice. The significance (Sig.) from one-
way ANOVA with Tukey’s multiple comparison test (-Tukey) are as follows: **** 








Figure 4.9. LynBKO mice have activated B cells. (A) H&E-stained splenic section from 
8-month-old mice. (B) Total B cells and (C) Total germinal center (GC) B cells per 
spleen of 8-month-old mice, relative to WT mice. (D) Fraction of B cells with a GC 
phenotypes (E) CD69 MFI and (F) MHCII MFI in B cells compared to WT mice. (G) 
CD69 MFI in GC B cells compared wot WT mice. The significance (Sig.) from one-way 
ANOVA with Tukey’s multiple comparison test (-Tukey) are as follows: **** P<0.0001, *** 






Figure 4.10. Lyn deletion affects T cell maturation and activation. (A) Total T cells, 
CD4+ and CD8+ T cells (B) Tregs, (C) and CD44+ CD4+ and CD8+ T cells per spleen of 
8-month-old mice, relative to WT mice. (D) Fraction of T cells that are CD44+. The 
significance (Sig.) from one-way ANOVA with Tukey’s multiple comparison test (-Tukey) 
are as follows: **** P<0.0001, *** P<0.0002, ** P<0.0021,* P<0.0332. Error bars 





4.2.4 Deletion of LynB predisposes mice to autoantibody production and 
glomerulonephritis 
LynKO mice develop an autoimmune disease similar to human SLE. LynKO plasma cells 
produce anti-nuclear antibodies (ANAs) that are deposited in the kidneys, causing 
immune-cell infiltration, activation, and the development of glomerulonephritis [111, 112, 
132]. 
 
We investigated whether they also developed symptoms of systemic autoimmunity. We 
tested serum from 8-month-old WT, LynAKO, LynBKO and total LynKO mice for the 
presence of ANAs by indirect immunofluorescence using Human Epithelial (HEp)-2 
substrate slides [260], modified for the detection of mouse anti-nuclear IgG. We found 
that the preponderance of LynBKO (10/12 mice) and LynKO (12/12) mice had high levels 
of ANAs (Figure 4.11A, B), whereas LynAKO and WT mice had rare instances of nuclear 
IgG staining. Because ANAs can be detected in healthy human populations in the 
absence of any autoimmune disease [261], we examined H&E-stained kidneys from 8-
month-old WT, LynAKO, LynBKO and total LynKO mice to detect immune-cell infiltration 
and fibrosis. A majority of kidneys from LynKO (5/6) and LynBKO (6/7) mice had evidence 
of immune infiltration, expanded glomeruli and tubular inflammation (Figure 4.11C, D), 
suggesting that the increased levels of ANA in the LynBKO mice do contribute to the 
development of autoimmune disease.  
 
Finally, we examined the total incidence of abnormalities (splenomegaly, ANA, and 
nephritis) in male and female knockout mice (Figure 4.12A). A majority of male and 
female LynBKO and LynKO mice had at least one severe finding, whereas only a small 
subset of WT (1/34 mice) and LynAKO (9/36) mice had any severe findings. These data 
further suggest that LynB, and not LynA, has a previously undescribed role in limiting 







Figure 4.11. Loss of LynB induces the development of anti-nuclear antibodies and 
glomerulonephritis. (A) Sera from 8-month-old WT, LynAKO, LynBKO and LynKO mice 
were used for detection of IgG ANAs on fixed Hep-2 ANA slides and imaged. Pictures 
are representative of 3 experiments. (B) Frequency of sera with ANA staining. 
Significance for raw contingency data was assessed using two-sided Fisher's exact test 
(GraphPad Prism) from binarized data reflecting animal numbers with no vs. severe ANA 
without correction for multiple comparisons. With Bonferroni Correction, significance is 
preserved in pairwise comparisons with the exception of [LynAKO vs. LynKO]. (C) Kidney 
sections from 8-month-old WT, LynAKO, LynBKO and LynKO mice were analyzed for signs 
of nephritis (H&E staining). Dashed boxes show areas enlarged in the bottom row.  (D) 
Frequency of kidneys with no, mild and severe cases of glomerulornephritis. 
Significance for raw contingency data was assessed using two-sided Fisher's exact test 
(GraphPad Prism) from binarized data reflecting animal numbers with no or mild vs. 
severe glomerulonephritis without correction for multiple comparisons. With Bonferroni 








Figure 4.12. Loss of LynB induces multiple symptoms of autoimmune disease. (A) 
Frequency of symptoms (ANA, splenomegaly or nephritis) in 8-month old male and 
female mice. Significance for raw contingency data was assessed using two-sided 
Fisher's exact test (GraphPad Prism) from binarized data reflecting animal numbers 
with no or mild vs. severe symptoms without correction for multiple comparisons. 
With Bonferroni Correction, significance is preserved in pairwise comparisons with 
the exception of [WT vs. LynAKO]. There were no significant differences in overall 





4.2.5 LynBKO and LynKO mice express higher levels of TLR4 and increased 
response to TLR ligation 
Activation of TLR by microbial ligands and signaling through MyD88 has been shown to 
induce the development of autoimmune disease in LynKO mice [117, 120, 183]. MyD88 
associates with multiple TLRs upon receptor ligation and links TLRs to cellular activation 
by recruiting downstream kinases and ubiquitin ligases that facilitate activation of NF-κB 
and other transcription factors. We probed whether immune cells in single-isoform 
knockout mice had changes in TLR protein expression. We examined TLR expression 
on immune cells in the blood of 8-month-old mice. Both LynBKO and LynKO mice had 
elevated TLR4 expression on multiple cell types, including neutrophils and patrolling 
monocytes (Figure 4.13C,D). Lyn has been shown to negatively regulate TLR4 signaling 
in dendritic cells [117, 119] but Lyn’s role in TLR4 signaling in monocytes and 
granulocytes has not been studied. Because we saw increased patrolling monocytes 
and dendritic cells in LynBKO and LynKO mice, dysregulated-TLR4 expression and 
signaling could be one driver of autoimmunity in these mice. LynAKO, LynBKO and LynKO 
mice had also have increased protein levels of TLR2 on patrolling monocytes (Figure 
4.13A) but only LynKO mice have increased TLR2 expression on classical monocytes. 
The pattern of TLR9 expression (Figure 4.13B) varied depending on the cell type: TLR9 
expression was decreased on LynAKO, LynBKO and LynKO patrolling monocytes, but only 
decreased on LynAKO and LynKO B cells 
 
To further probe whether LynB-deficient mice had increased responsiveness to TLR 
ligation, we treated splenocytes ex vivo with LPS or CpG-oligonucleotides to induce 
TLR4 or TLR9 signaling, respectively. We then used flow cytometry to examine the cells 
that produced TNFα upon stimulation. As expected, a significant number of pDC were 
TNFα+ in response to either LPS or CpG treatment (Figure 4.13E), whereas other cell 
types were more variable (Figure 4.13F). We discovered that a higher percentage of 
pDC in LynBKO were TNFα+ in response to CpG (55% in LynBKO, compared to 38% in 
WT mice) (Figure 4.13G), while a higher percentage of patrolling monocytes in LynBKO 
were TNFα+ in response to CpG and LPS (Figure 4.13G). pDC are potent cytokine 
secretors and can drive autoimmune disease [259]. LynBKO mice in particular have 
increased numbers of spleen pDC. Increased TLR responsiveness and numbers of pDC 
may be one element that drives autoimmune disease in LynBKO mice. The pattern of 
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TNFα responsiveness was variable in other cell types (Figure 4.14A-D), but in general 
LynKO and LynBKO cells were more responsive to TLR4 and TLR9 stimulation. These 
data further confirm that LynB, and not LynA, negatively regulates TLR signaling and 





Figure 4.13. LynBKO mice have higher TLR4 expression and increased response to 
TLR stimulation (A) Relative MFI of TLR2, (B) TLR9, (C) and TLR4 in circulating 
immune cells from 8-month-old WT, LynAKO, LynBKO, and LynKO mice. (D) 
Representative histogram of TLR4 expression on patrolling monocytes. (E) 
Representative histogram of WT pDC treated with vehicle, LPS and CpG. (F) 
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Representative histograms of WT, LynAKO, LynBKO, and LynKO mice pDC treated with 
CpG and patrolling monocyte treated with LPS. (G) Quantification of TNFα+ pDC and 
patrolling monocytes treated with CpG and LPS. The significance (Sig.) from two-way 
ANOVA with Tukey’s multiple comparison test (-Tukey) are as follows: **** P<0.0001, *** 






Figure 4.14. LynBKO splenocytes have increased responsiveness to TLR 
stimulation (A) Quantification of TNFα+ cDC1, (B) cDC2, (C) neutrophils and (D) 
eosinophils treated with CpG and LPS. The significance (Sig.) from two-way ANOVA 
with Tukey’s multiple comparison test (-Tukey) are as follows: **** P<0.0001, *** 






































In this chapter we report that the protein splice-variants of lyn, LynA and LynB, have 
different roles in preventing the development of autoimmune disease. Until now there 
have been no reliable in vivo models to independently study LynA and LynB signaling. 
Using CRISPR-Cas9 gene editing we created two novel knockout models, LynAKO and 
LynBKO mice. To our knowledge, this is the first use of CRISPR to create global knockout 
models to alter expression of splice-variants from the same gene. Our novel mouse 
strains retain the regulatory gene elements of the lyn gene and are expressed at wild-
type levels in immune cells. 
 
Previous research has demonstrated that Lyn has prominent roles in both activating and 
dampening immunoreceptor signaling. Lyn is activated following BCR and FcR signaling 
and can phosphorylate secondary kinases such as Syk, or second-messenger 
generators such as PI3K and PLCγ1/2. However, Lyn can also recruit and activate 
phosphatases, such as SHP-1 and SHIP-1, that dephosphorylate tyrosines and lipids, 
dampening immunoreceptor signaling. LynKO mice develop an autoimmune disease with 
symptoms similar to human lupus, including the production of anti-nuclear antibodies 
which cause glomerulonephritis. Previous research from our groups and others has 
demonstrated that LynA and LynB are differentially regulated in macrophages [22, 27] as 
well as Mast and B cells [42, 148]. Other work has suggested that LynA and LynB have 
the propensity to activate different signaling cascades [149, 150]. These studies have 
suggested that LynB associates with and phosphorylates inhibitory proteins such as 
SHIP-1, while LynA more readily activates signaling pathways that may produce an 
immune response. Using these novel mice strains, we show that LynA and LynB have 
unique roles and that LynB is required for preventing autoimmunity. 
 
We discovered that both LynKO and LynBKO mice had increased presence of ANAs, more 
pronounced glomerulonephritis, and increased development of splenomegaly compared 
to WT and LynAKO mice. Knocking out either LynA or LynB resulted in pronounced 
changes to the immune system. While LynKO mice have a defect in B cell development, 
expression of either isoform restored the numbers of B cells. However, while mature B 
cells in LynKO mice were more likely to become activated plasma cells, LynBKO mice had 
both increased plasma cells, as well as GC B cells. Both LynAKO and LynBKO mice had 
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more CD4 and CD8 T cells in the spleen, which might be due to the fact that LynAKO and 
LynBKO mice had more cDCs than WT mice. Interestingly, while previous research has 
shown that Lyn negatively regulates the development of myeloid cells such as 
neutrophils, eosinophils and monocytes, we did not detect an increase in those cell 
types in either LynAKO or LynBKO mice, with the exception that LynBKO mice had more 
patrolling monocytes than WT mice. We did however detect an increased population of 
pDCs in LynBKO mice, and pDCs are known to contribute to autoimmune disease [259]. 
 
Because TLR signaling can drive splenomegaly and autoimmune disease in the 
absence of Lyn, we investigated TLR expression in LynAKO and LynBKO mice and 
discovered increased expression of TLR4 in multiple circulating immune cells in LynBKO 
and LynKO mice. Previous research has not detected different levels of TLR4 expression 
on immune cells in LynKO mice [256], although these reports have focused on different 
immune cells than we have, and should be investigated more extensively. Lyn is known 
to negatively regulate TLR4 signaling [119, 124, 262]. It is possible that the increased 
surface expression of TLR4 is due to altered inflammatory environments in the LynBKO 
and LynKO mice that promote splenomegaly and autoimmune disease. We further 
discovered the LynBKO and LynKO mice had enhance responses to TLR4 and TLR9 
stimulation, particularly in monocytes and pDCs, suggesting that increased expression of 
TLR4 and altered TLR signaling drive autoimmunity in LynB-deficient mice. Because we 
saw an increase both the numbers of spleen pDC and the pDC response to TLR 
stimulation in LynBKO mice, this suggests LynB plays a unique role in negatively 
regulating pDC function and pDC role in autoimmunity. 
 
In summary, we used CRISPR-Cas9 to constrain splicing of Lyn, developing the first 
models to independently study LynA and LynB signaling in vivo. We demonstrate that 
LynB restricts the development of autoimmune disease and negatively regulates TLR 
signaling. These mice strains will be useful tools to investigate the mechanisms by which 
LynB uniquely prevents autoimmunity and will deepen our understanding of the 




CHAPTER 5:  Discussion 
5.1 Future Directions 
My thesis work has elucidated unique regulatory mechanisms and functions of the two 
proteins, LynA and LynB, formed by alternative splicing of the lyn transcript. I have 
shown that phosphorylation of Y32, in the unique region of LynA, induces interaction 
with a ubiquitin ligase, c-Cbl, causing LynA to be rapidly and specifically poly-
ubiquitinated and degraded upon activation. I have shown that selective expression of 
cbl-family members in different immune cells controls the rate of LynA degradation and 
subsequent downstream signaling responses. In macrophages, high expression of c-Cbl 
causes LynA to be degraded rapidly and prevents signal cascade propagation. However, 
in mast cells, low c-Cbl and high Cbl-b expression causes LynA to be degraded slowly, 
leading to elevated signaling. I have also shown that phosphorylation of Y32 requires 
SFK signaling and is likely a site of trans-phosphorylation by the SFKs.  
 
Previous research suggests that LynA and LynB have a propensity to activate different 
signaling cascades. In mast cells, LynA was better able to increase intracellular free 
calcium upon FcεR ligation, whereas LynB associated with, and phosphorylated, 
inhibitory proteins such as SHIP-1 [149]. However, studying the roles for LynA and LynB 
in immune cells had been hampered by a lack of animal models in which LynA and LynB 
are selectively knocked out. In this dissertation, I have described our work creating novel 
LynAKO and LynBKO mice using CRISPR/Cas9 gene editing to constrain alternative 
splicing. I discovered that loss of LynB particularly prevented mice from developing 
splenomegaly and symptoms of autoimmune disease, including the production of anti-
nuclear antibodies and the development of glomerulonephritis. Furthermore, deletion of 
either LynA or LynB resulted in altered immune populations. Both LynAKO and LynBKO 
mice had elevated numbers of T and B cells in their spleens, while LynBKO mice had 
increased numbers of germinal center B cells, cDC2 and plasmacytoid dendritic cells. 
Furthermore, a higher percentage of LynBKO pDC and monocytes were TNFα+ when 
treated with TLR4 and TLR9 agonists. These results point to differential roles for LynA 
and LynB in regulating immune cell proliferation and activation, particularly for LynB in 




My thesis work demonstrates unique features of LynA and LynB regulation and signaling 
that are important for immune function. By demonstrating that c-Cbl controls the protein 
levels and signaling capacity of LynA, I have demonstrated that differential expression of 
cbl-family members regulates immune function, which has implications for strategies that 
attempt to alter immunoreceptor signaling, such as chimeric-antigen receptor (CAR)-T 
cells. By demonstrating that mast cells express low levels of c-Cbl and high levels of 
LynA which result in enhanced signaling responses upon SFK activation, my work 
suggests that therapies that increase c-Cbl expression in mast cells or enhance SFK 
poly-ubiquitination and degradation may help resolve allergic diseases. 
 
I have further demonstrated that LynB has a strong negative-regulatory role in immune-
cell activation. Understanding how LynB mediates this unique function will aid our 
understanding of the cells and pathways involved in autoimmunity. One of the major 
adverse effects of current therapeutics for autoimmune-related diseases is immune 
suppression. LynAKO (LynB-expressing) mice do not develop autoimmunity but are 
rescued from the many immune defects present in LynKO mice. Understanding how LynB 
prevents autoimmunity and rescues these defects will improve our ability to develop 
therapeutics that selectively modulate signaling thresholds in immune cells to prevent 
aberrant activation but retain pathogen-clearing abilities.  
 
Despite these advances, our understanding of LynA and LynB function remains 
incomplete. In the following sections I will discuss several directions for research 
dissecting the roles for LynA and LynB in different aspects of immunity. 
 
5.1.1 LynA and LynB signaling and interactome 
The one previous attempt to characterize the contribution of LynA and LynB to 
immunoreceptor signaling relied on lentiviral expression of LynA or LynB in LynKO cells 
[149]. These studies revealed novel roles for LynA and LynB in immunoreceptor 
regulation. However, a lack of in vivo models to study LynA and LynB independentaly 
has prevented studying signaling pathways in cells that are resistant to lentiviral-Lyn 
expression, including macrophages [22]. However, the novel LynAKO and LynBKO mice, 
described in this dissertation, are reliable tools to study the precise signaling pathways 




I have shown that phosphorylation of LynA at Y32 (absent in LynB) uniquely recruits the 
ubiquitin ligase c-Cbl to poly-ubiquitinate LynA and leads to the rapid degradation of 
LynA in macrophages [27]. Although these studies (and others) suggest unique protein-
protein interactions that differentiate LynA and LynB, one of the major unanswered 
questions of this work was comprehensive understanding of those interactions and how 
those interactions modulate immunoreceptor signaling and cell activation. We have now 
bred the LynAKO and LynBKO strains to generate CskASLynAKO and CskASLynBKO which 
express an inhibitable form of Csk from a transgene. After treating macrophages from 
these mice with 3-IB-PP1 to induce SFK activation, two approaches could be taken to 
investigate LynA and LynB signaling and interaction: interactomics and 
phosphoproteomics. Co-immunoprecipitation of either Lyn isoform, followed by protease 
digestion and mass spectrometry could reveal differences in their interactomes. Such 
approaches have been successful with lentivirally-expressed LynA and LynB in breast 
cancer cells [150], revealing distinct interaction patterns for the two isoforms. Although 
this study revealed that LynA is more likely to interact with proteins that modulate actin 
dynamics, one could argue that these methods could fail to identify meaningful protein-
protein interactions, because kinase-substrate phosphorylation and interaction occur on 
relatively short time scales and may be missed by co-immunoprecipitation. Therefore, a 
broad tandem mass-spectrometry-based phosphoproteomics approach [165, 167, 263] 
(Figure 5.1) could be used to reveal the specific proteins, and specific sites of 
phosphorylation, phosphorylated following either LynA or LynB activation. 
 
The beauty of these two approaches is that they can be applied to multiple cell types. 
Treatment of CskAS cells with 3-IB-PP1 induces broad SFK signaling and the activation 
of multiple pathways, which is useful for identifying the extent of substrates 
phosphorylated downstream of LynA and LynB activation. However, targeted 
approaches, such as a phosphoproteomic analysis of TLR4 and TLR9 receptor ligation 
could reveal insights as well. There is ample evidence to suggest that Lyn signaling 
differentially regulates TLR signaling in macrophages vs. dendritic cells [117, 119]. While 
LynKO dendritic cells had increased levels of Erk phosphorylation following treatment with 
LPS, TLR4 signaling did not appear to be negatively regulated by Lyn in macrophages. 
These approaches could elucidate the differences in LynA and LynB signaling between 
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these two cell types, giving us a more complete understanding of the importance of LynA 
and LynB in regulating cellular activation. 
 
A third approach to understand LynA and LynB signaling would be to use RNA 
sequencing (RNAseq) to identify differentially regulated transcripts in LynAKO and LynBKO 
cells. RNAseq uses high-throughput sequencing to identify the transcriptional state of 
bulk cell populations [264], and can be combined with cell sorting methodologies to 
identify transcriptional patterns in single cell populations (scRNA-seq). In Chapter 4, we 
identified numerous changes in the immune system of LynAKO and LynBKO mice, 
including increased expression of TLR4 in circulating LynBKO cells, and increased pDCs 
in the spleens of LynBKO mice. Both bulk RNAseq and scRNAseq could be leveraged to 
identify whether TLR4 expression is increased due to transcriptional changes in LynBKO 
mice and elucidate whether the pDCs in LynBKO mice are functionally different from 
those in LynAKO and WT mice.  
 
In summary, co-immunoprecipitation and phosphoproteomics approaches, along with 
RNAseq, will help identify the different protein-protein interactions, signaling dynamics, 
and transcriptional changes of immune cells in LynAKO and LynBKO mice, giving us a 







Figure 5.1. Conceptual framework for phosphoproteomic analysis of LynA and 
LynB signaling. Mass-spectrometry-based identification of phosphorylated peptides in 
cells from LynAKO and LynBKO mice could be used to identify enriched signaling 





5.1.2 LynA and LynB in B-cell dynamics  
By acting as a regulator of both the BCR and TLRs, Lyn signaling must be tightly 
controlled for proper B cell maturation and activation. Lyn deficiency in mice prevents the 
proper maturation of Pro/Pre-B cells towards mature B cells [132], but also predisposes 
mature B cells to become activated plasma cells that may secrete auto-reactive 
antibodies [118]. Mature follicular LynKO B cells have delayed but increased signaling 
responses, as measured by increases in free intracellular calcium, following BCR 
ligation, but there is little knowledge about how LynA and LynB impact BCR signaling, B 
cell maturation, B cell activation and various B cell responses. I have shown the 
expression of either isoform restores the defect in B cell maturation, and in the case of 
LynAKO mice, actually results in an increased number of B cells in the spleen. However, 
whether these findings are due to intrinsic effects of LynA or LynB signaling in the B cells 
themselves, or due to LynA/LynB deficiency in other cell types that create a more 
permissive environment for B cell proliferation in the spleen remains unknown. 
 
The repertoire of mature B cells and autoreactive plasma cells in LynKO mice has been 
relatively understudied. The developmental defect in B cell maturation in LynKO mice 
suggests that mature LynKO B cells and plasma cells might be dominated by relatively 
few clones and a less diverse repertoire compared to WT mice. Autoreactive plasma 
cells have limited clonality in other models [265] but how autoreactive Lyn-deficient B 
cells escape tolerance and whether there is limited clonality is unanswered. Failure to 
create a productive BCR that induces sufficient PI3K signaling causes B cells to die by 
neglect. Lyn has been shown to be critical for promoting PI3K signaling in B cells [104], 
suggesting that lack of Lyn may promote B cell death at this early stage. Under normal 
circumstances, highly autoreactive B cells undergo receptor editing in the bone marrow, 
mutating the antibody light chain fragment to create a less autoreactive BCR [266]. 
Despite this negative selection process, an estimated 10-15% of (human) B cells that 
exit the bone marrow possess self-reactive BCRs [267]. I have shown that LynBKO mice 
express normal levels of B Cells, but still develop nephritis from ANA deposition. 
Whether this is driven by a select few autoreactive clones that end up making it to the 
periphery and escape central tolerance mechanisms, or whether the cells that make it 
past negative selection in LynBKO have a limited repertoire, should be investigated 
further. Understanding the BCR arrangements that promote autoimmunity in LynKO and 
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LynBKO mice will aid our understanding of the antigens and signals involved in 
autoreactive B cell development. 
 
Interestingly, self-reactivity/tonic signaling seems to be required for normal B cell 
function [268]. By using a model that drives GFP expression in response to transcription 
of the protein, Nur77, the Zikherman lab showed that mature follicular B cells respond to 
self-antigens at steady state. In B cells, Nur77 transcription is driven by BCR signaling, 
and importantly, not by TLR signaling. Thus, Nur77-driven GFP expression can be used 
to reliably measure BCR activity in vivo. Interestingly, this model showed that Lyn-
deficient B cells express high levels of Nur77 at steady state, suggesting either high 
levels of tonic BCR signaling or an increased response to self-antigens. The Zikherman 
lab further demonstrated that IgM expression was required for ANA production and the 
direction of LynKO B cells towards a short-lived plasma cell (SLPC) phenotype. Because 
we saw differences in the number of mature B cells in LynAKO and LynBKO mice, it is 
intriguing to suggest that each isoform may have different roles in regulating tonic 
signaling or may modulate signaling downstream of different BCR classes. Identifying 
the level of Nur77-GFP expression in mature LynAKO and LynBKO B cells would help 
clarify whether there is an increase in self-reactivity and the contribution of LynA and 
LynB to tonic BCR signaling. Further experiments with Nur77-GFP mice may help 
elucidate how BCR signaling in LynBKO mice generates more GC B cells than WT and 
LynKO mice. 
 
B cell fate upon antigen exposure is highly dependent on BCR affinity. Strong BCR 
signaling (high affinity) predisposes B cells towards a SLPC fate, while low affinity drives 
B cells towards a GC fate [269, 270]. Because we saw an increase in GC B cells in the 
LynBKO mice, this suggests LynA signaling may alter affinity sensing by the BCR in 
response to antigen activation. Adoptive transfer of either LynAKO or LynBKO B cells into 
WT host mice, followed by vaccination would answer many questions about the fate of 
LynAKO and LynBKO B cells in response to antigen stimulation: whether intrinsic LynA or 
LynB deficiency predisposes B cells to GC fates, and whether these cells produce high-




In macrophages, phosphorylation of LynA Y32 recruits the ubiquitin ligase c-Cbl. This 
interaction offers potentially intriguing insights to the B cell germinal center response. In 
B cells, both c-Cbl and Cbl-b are required for ubiquitination of the BCR, which causes 
BCR-surface downregulation, and is required for normal GC entry and dynamics [94, 
95]. Data from Immgen (Figure 5.2) suggests that Cbl and Cblb expression are 
differentially regulated in B cells and shows that Cbl expression peaks in GC B cells. 
Because of the close interaction between LynA and c-Cbl in macrophages, it is tempting 
to suggest that LynA may be required for proper c-Cbl activation in germinal center B 
cells, BCR downregulation and GC dynamics. Interestingly, LynBKO (LynA-expressing) 
spleens have more GC B cells (Figure 4.9) and a higher proportion of GC B cells. 
However, this could be caused by a multitude of cell changes in these total-LynBKO 
animals. Future studies should examine whether B cell receptor trafficking is altered in 
LynAKO and LynBKO mice, and whether these mice are able to form efficient germinal 







Figure 5.2. c-Cbl, and Cbl-b mRNAs are differentially regulated in B cells. Mouse 
RNAseq data derived from the Immunological Genome Project [ImmGen, 
http://rstats.immgen.org/Skyline/skyline.html, 226, 227]. RNA levels of c-Cbl, and Cbl-b 
are shown for B cell subsets, Germinal center (GC) B cells are boxed. RNA values are 
computed as a fraction of the maximum expression value, normalized by DESeq2, 





5.1.3 Lyn, TLR signaling, commensals, and autoimmunity 
TLR signaling is a potent driver of both human autoimmune disease [126, 252], and 
autoimmune disease in Lyn-deficient mice [120, 122]. TLR signaling in both B cells and 
dendritic cells is sufficient to drive the development of ANA and nephritis [117, 118], 
illustrating that Lyn regulates TLR signaling in multiple cell types. I have shown that 
LynBKO mice also develop aspects of autoimmune disease and have elevated responses 
to TLR4 and TLR9 stimulation, depending on the cell type. Despite these observations, 
the mechanisms linking LynA and LynB to TLR signaling, and TLR signaling to 
autoimmune disease in LynB-deficient mice, are not well understood. 
 
The primary function of TLRs is to sense components of bacterial, viral, and fungal 
pathogens. The mice used in ours and other studies were housed in specific-pathogen-
free (SPF) facilities, in the absence of pathogens that could potentially create an 
inflammatory environment. Previous research has shown that LynKO mice given dextran 
sulfate sodium (DSS) in their drinking water fatally succumb to colitis, whereas wild-type 
mice survive [119]. DSS induces colitis by disrupting mucus function and increasing 
commensal-bacterial translocation across the digestive epithelium [271]. Whether 
specific commensal viral/fungal/bacterial species drive TLR activation and autoimmune-
disease development in LynKO mice remains unanswered, but the premise is intriguing. 
 
Changes to the microbiome have been linked to the development and severity of 
autoimmunity in humans [272-274]. Specific bacterial species, such as Prevotella copri, 
have been linked closely to select diseases such as rheumatoid arthritis (RA) [273], 
while a large number of bacterial genii have links to SLE in particular [273]. These 
studies suggest that sensing of specific bacteria by TLRs could play a role in 
autoimmune disease. However, studies from human twins also suggest that genetic 
factors, as opposed to environmental (commensal bacteria), pose the greatest risk for 
developing autoimmune disease, particularly in human SLE [275]. Commensal bacteria 
could drive disease in LynB-deficient mice through two (non-mutually exclusive) main 
mechanisms. In one circumstance, specific commensals may trigger TLR signaling that 




In another circumstance, B cells may make commensal-self cross-reactive antibodies 
that drive disease in the absence of properly functioning central tolerance mechanisms. 
Cross-reactive antibodies have been demonstrated for RA and Sjogren’s syndrome 
[273, 276] but have not been identified in LynKO mice. It would be interesting to examine 
whether autoantibodies in LynKO and LynBKO mice also target commensal antigens by 
analyzing microbiota-reactive antibodies in the mouse feces via flow cytometry [277]. A 
failure to develop tolerance to commensals has been linked to worse disease outcome 
later in life [278]. It is unknown whether LynB impacts commensal tolerance, but it’s 
tempting to suggest that a breakdown in tolerance, via altered dendritic-cell and B-cell 
phenotypes, contributes to T cell activation and the development of autoimmune disease 
upon aging in LynKO and LynBKO mice. Future experiments should investigate whether T 
cells and B cells in LynKO and LynBKO mice have TCRs and BCRs specific for 
commensal antigens, and whether these cells have a more activated phenotype than 
those in WT mice. 
 
Interestingly, multiple epidemiological studies in humans and experiments with different 
infectious agents and TLR agonists in mice suggest that pathogen exposure may play a 
protective role in autoimmune disease [279]. The ’hygiene hypothesis’ suggests that 
activation of the immune system by pathogens, particularly through TLRs, can drive 
tolerance mechanisms that limit exuberant immune responses later in life. It is unknown 
whether Lyn or LynB signaling affects TLR tolerance, although one study has suggested 
that tolerance decreases phosphorylation of Lyn following TLR4 activation [280]. Future 
studies should examine whether microbial exposure regulates the incidence of 
autoimmune disease in LynBKO and LynKO mice. Treating these knockout mice with 
antibiotics to deplete commensal bacteria could theoretically improve autoimmune 
disease severity by decreasing the exposure to TLR ligands, thereby limiting activation 
of immune cells via TLR signaling. Conversely, treating mice with antibiotics may 
prevent some semblance of TLR tolerance from occurring. In contrast, normalizing the 
microbial exposure (NME) with so-called “dirty mice” [281] may induce tolerance 
mechanisms that prevent aberrant TLR signaling in LynB-deficient mice. Although it is 
probably more likely that LynB-deficient mice might fatally succumb more rapidly upon 
NME due to B cell defects and increased cytokine production in response to TLR4/9 
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5.2 Concluding remarks 
facilis descensus Averno; noctes atque dies patet atri ianua Ditis; sed revocare gradum 
superasque evadere ad auras, hoc opus, hic labor est. 
 
The descent from Avernus is easy; the black door of Ditis stands open night and day; but 
to return and to escape to heavenly skies, this is the work, this is the struggle. 
 
Virgil, The Aeneid 
 
By Book XI of Virgil’s Aeneid, the titular, duty-bound Aeneas is a wearied traveler. And 
although he finds himself currently displaced, he is yet endowed by divine providence for 
future glory. Having escaped the fall of Troy and having been buffeted by wind, sea, and 
divine forces from port to port, Book XI sees Aeneas seeking divine guidance in search 
of a final stopping point on his long journey. He makes sacrifices to the gods, performs 
augury to interpret coded meanings of natural phenomena, and he even journeys 
through the gates of the underworld, Averno, to seek guidance from his deceased father, 
all to fulfill the duty set upon him by his divine forebears: founding the empire that would 
become Rome. The lives of the cells of our immune system have striking similarities to 
the journeys of Aeneas and his fellow Trojan refugees. Immune cells are “duty-bound” 
from differentiation to protect the body from pathogenic insults and respond to tissue 
inflammation. They circulate through their own Mare Nostrum, blood and lymph, in 
search of a home and purpose. And just like Aeneas surveys both the natural and 
infernal worlds, immune cells sense and respond to environmental cues, including those 
from dead and dying cells, which activate receptors that direct immune cell function. 
These receptors often trigger the activation of tyrosine kinases that propagate signaling 
cascades that direct an immune response. The Src-family kinases (SFKs) are a group of 
non-receptor tyrosine kinases important for many aspects of an immune response, 
including T cell recognition of antigen bound to MHC, activation of B cells by antigen 
binding to the B cell receptor, and phagocytosis by myeloid cells. The Src-family kinase 
Lyn is an important regulator of the responses initiated by many immunoreceptors and is 
a key regulator of immune function. Lyn is unique among the Src-family kinases due its 
ability to both activate immunoreceptor signaling, by recruiting and phosphorylating 
phosphoinositide kinases and phospholipases, and dampen immunoreceptor signaling, 
primarily by recruiting phosphatases that limit cascade propagation. Alternative splicing 
of the lyn transcript yields two proteins, LynA and LynB, that are well-conserved in 
mammals. My thesis has demonstrated unique regulatory mechanisms that selectively 
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control the protein levels of active LynA, in contrast to LynB and other SFKs. 
Furthermore, my thesis research has demonstrated unique roles for both LynA and LynB 
in regulating the development and maturation of immune cells, the development of 
autoimmune disease in mice, and TLR signaling. During the Trojan War, Aeneas is 
rescued from imminent harm on two separate occasions by both of the twin deities, 
Apollo and Artemis. As twins, Apollo and Artemis both share predilections towards 
archery, and supported the Trojans, as opposed to the Greeks during the famous war. 
However, Apollo and Artemis are also partial to their own dedicated pursuits. Similarly, 
LynA and LynB can play both similar and divergent roles in immune function, dependent 
on both the cell type and signaling pathway being studied (Figure 5.3). Understanding 
how cells balance the positive and negative signaling induced by these isoforms will help 
us understand the mechanisms by which the immune system preserves pathogen 
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